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ABSTRACT
Recent advances in development of nanomaterials have provided great opportunities for
cancer research. In this dissertation, nanoGUMBOS derived from a group of uniform materials
based on organic salts (GUMBOS) were investigated for several biomedical applications including
chemotherapy, photothermal therapy (PTT), and drug delivery. GUMBOS are solid-phase organic
salts consisting of bulky cations and anions. Similar to ionic liquids, GUMBOS display highly
tunable properties with counter-ions variation, but with a defined melting point range of 25–250 °C.
Nanomaterials derived from GUMBOS, i.e. nanoGUMBOS, display enhanced properties at the
nanoscale level. This dissertation focuses on development of near infrared IR780 nanoGUMBOS
for biomedical applications.
Firstly, several IR780-based GUMBOS were synthesized and characterized with tunable
physicochemical properties. Using hydrophobic properties of these GUMBOS, nanoGUMBOS
were directly prepared using a reprecipitation method. Examination of in vitro cytotoxicity
indicated enhanced selective toxicity of nanoGUMBOS towards cancer cells with minimum
toxicity towards normal cells, as compared to traditional IR780. Results from this study
demonstrate that simple counter-ion variation can enhance chemotherapeutic effects.
Encouraged by promising in vitro chemotherapeutic properties of IR780-based
nanoGUMBOS, extensive studies using cyclodextrin(CD)-based IR780 nanoGUMBOS for
chemo/photothermal antitumor effects were explored. Such nanoGUMBOS displayed several
enhanced physical, chemical, and biological properties as compared to nanoGUMBOS without
CD. Most importantly, remarkable chemo/photothermal therapeutic effects were observed for CDbased IR780 nanoGUMBOS both in vitro and in vivo.

v

Finally, a PEGylation approach was employed for fabricating PEGylated IR780-based
nanoGUMBOS as multifunctional drug carriers. Herein, a hydrophobic anticancer drug, paclitaxel
(PTX), was loaded into nanoGUMBOS for evaluation of their capability for drug delivery.
Intriguingly, GUMBOS with greater hydrophobicity resulted in formation of nanoGUMBOS with
higher drug loading and more sustained drug release. In vitro cytotoxicity studies indicated
significantly enhanced anticancer activity for PTX-loaded nanoGUMBOS as compared to free
PTX. Thus, these results confirm efficient delivery of PTX to cancer cells. Moreover, these
nanoGUMBOS displayed intense fluorescence emission in the near infrared region, selective
toxicity towards cancer cells, and mitochondria targeting properties, thus confirming the
multifunctionality of naoGUMBOS. These results suggest a promising approach through
simultaneous use of GUMBOS and PEGylation to develop multifunctional nanocarriers.

vi

CHAPTER 1. INTRODUCTION
1.1. Cancer and Current Treatments
According to the latest global statistics, more than eight million people worldwide die
every year from cancer.1 Despite rapid developments of several advanced cancer treatments, the
number of cancer related deaths is expected to continue to grow, and can possibly reach 13
million per year by 2030 due to rapid expansion and aging of the world’s population.2 Cancer
refers to a collection of heterogeneous diseases characterized by uncontrolled division and
growth of cells resulting from a series of genetic mutations within normal cells.3 Two categories
of genes play a major role in triggering cancer: proto-oncogenes that promote cell division and
tumor suppressor genes that inhibit cell division. Normally, these genes coordinate to ensure
controlled cell division, cell growth, and programmed cell death. Thus, a balance in the size and
structure of each tissue and organ can be maintained as required for a healthy body.4-5 However,
mutations in these two categories of genes lead to formation of oncogenes that stimulate
excessive divisions as well as interrupt inhibitory signals.6 Normally, the inhibitory signals
counter-balance the growth-signaling pathways such as apopotosis, a form of programmed cell
death. As these mutations accumulate over and over, normal cells are progressively transformed
into cancer cells, ultimately resulting in production of a large population of cells that are
recognized as a tumor. This process is illustrated in Figure 1.1.
Tumors can either be benign or malignant. Benign tumors grow locally and lack the
ability to invade adjacent tissues. In contrast, malignant tumors are a mass of cancerous cells that
are highly invasive towards nearby tissues. These cells can also metastasize into distant sites in
the body via blood stream, circulatory system, and lymphatic system. As a result, new colonies
of cancer cells termed metastases are established.7 In this scenario, without immediate control of
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such metastasis, the entire body will be quickly invaded by cancer cells, making treatment
difficult.

Normal

Mutation

Tumor

Figure 1.1. Schematic representation of oncogenesis.
Several cancer treatments have been developed, aiming to control growth or spread of
cancer cells. The most common treatment methods include surgery, radiotherapy,
immunotherapy, and chemotherapy.8 Surgery involves excision of tumor from the body,
ultimately diminishing cancer symptoms. Radiotherapy uses high energy X-rays or gamma rays
to kill cancer cells and/or slow the growth of cancer cells by damaging DNA. Immunotherapy
refers to the use of drugs, vaccines, or antibodies that can exploit the immune system to act
directly against cancer. Chemotherapy is the use of chemotherapeutic drugs to kill or inhibit
cancer cell proliferations, which can work throughout the whole body. These treatment methods
have been demonstrated to be effective for cancer therapy and have benefited millions of cancer
patients by improving their quality of life as well as prolonging their lives.9 However, there are
limitations when using these treatments. For example, removal of tumor using surgery may result
in tumor recurrence due to the possibility of incomplete removal of cancer cells.10 Thus,
radiotherapy or chemotherapy is extensively used as a palliative treatment. However, these
subsequent treatments not only kill cancer cells, but also produce harmful effects to healthy cells
that result in a series of severe side effects such as fever, nausea, hair loss, and infertility.11-12 In
some cases, cancer patients die from side effects of treatments rather than the cancer, severely
hindering application of these treatments for cancer therapy. Meanwhile, the emergence of
2

multidrug resistance (MDR) dramatically decreases drug efficacy, thus limiting the success of
chemotherapy.13 Therefore, it is highly desirable to develop alternative targeted therapeutics that
can achieve efficient drug efficacy and reduced side effects. Herein, incorporation of
nanotechnology for design of such therapeutic drugs has been proposed and investigated in this
dissertation.
1.2. Nanotechnology for Cancer Treatment
Nanotechnology refers to the science and engineering of manipulating matters at
nanometer (nm) scale ranging from 1 nm to 100 nm.14 In general, as the material is miniaturized,
its properties such as size, shape, and surface structure change dramatically, all of which also
result in many other parallel changes in physical, chemical, and biological properties.15
Specifically, when the material is reduced to a nanoparticle, the nanoparticle can possess many
unique properties relative to its bulk counterpart; such as, large surface to volume ratio, high
reactivity, and unique optical, thermodynamic, and magnetic behaviors.16-17 By taking advantage
of these unique properties, nanoparticles have been widely employed for various applications.18
One of the most impactful applications of nanoparticles is in nanomedicine. This field involves
use of nanoparticles to develop novel and efficient diagnostic and therapeutic modalities that can
further improve current detection and treatments for a variety of diseases, especially cancer.19
Advantages of nanoparticles in medicine are numerous because of their tunable properties
including size, shape, and surface functionalization. For instance, novel designed nanoparticles
as imaging modalities can allow identification of various abnormalities such as precancerous
cells and disease biomarkers that are not detectable by conventional methods.20 As reported by
Harisinghani et al., a dextran coated superparamagnetic iron oxide (SPIO) nanoparticle was
developed as a magnetic resonance imaging (MRI) contrast agent. Using this SPIO nanoparticle,
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they successfully detected and visualized small metastases in the lymph node of a human
prostate cancer patient that were only vaguely observed by conventional MRI.21 In addition,
nanoparticles can be designed as drug carriers (i.e. nanocarriers) with several distinct advantages
for enhanced therapeutic efficacy. At first, nanocarriers improve the solubility of hydrophobic
drugs and thus the bioavailability.22 Their size, shape, or surface can also be modified to protect
encapsulated drug molecules from degradations due to natural metabolic processes, thus
substantially prolonging the life time of their systemic circulation.23 Additionally, manipulation
of size and surface properties of nanocarriers allows for targeting delivery of drugs to tumor sites
through passive and/or active targeting pathways, which can significantly minimize side effects.
Passive targeting is a means by which nanocarriers can enter tumors due to the unique leaky
vasculature and the reduced lymphatic drainage of solid tumors. Such targeting mechanism
primiarly relies on the enhanced permeation and retention (EPR) effects. Active targeting
employs the ligand-receptor interaction. In this case, nanocarriers are functionalized with
targeting ligands on the surface that can strongly bind to the specific receptors expressed by
tumor cells.24-25 Furthermore, nanocarriers also have the capability to simultaneously deliver two
or more drugs in a single dose. As a result, combination therapy can be employed using such
nanocarriers to produce a synergetic effect.20 Overall, using these nanoparticles for cancer
treatment has shown great potential in revolutionizing how we diagnose and treat cancer.
1.2.1. Typical Nanocarriers for Cancer Treatment
Nanoparticles are typically designed as nanocarriers for drug delivery in cancer
treatment. These nanocarriers including but not limited to liposomes, micelles/polymeric
micelles, and dendrimers are primarily discussed here (Figure 1.2). Each possesses various
unique characteristics such as composition, shape, and structure, all of which make these
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nanoparticles highly flexible for biomedical applications. For example, liposomes, also defined
as nanosized phospholipid vesicles, consist of at least one lipid bilayer with an enclosed aqueous
core. These vesicles have a unique ability to encapsulate either hydrophilic compounds in their
aqueous core, or hydrophobic agents in the bilayer membrane, thus allowing for delivery of
diverse drugs to cells.26 Several liposomal formulations of anticancer drugs have demonstrated
the successful delivery of drugs to tumor sites with minimum side effects in comparison with
traditional drugs. For example, Doxil involved use of PEGylated liposome as a drug carrier to
deliver chemotherapeutic agent doxorubicin. This liposomal formulation was approved by the
Food and Drug Administration (FDA) for treatment of Kaposi's sarcoma, recurrent ovarian
cancer, and breast cancer.27
Micelles, particularly polymeric micelles, have also been extensively investigated as drug
carriers because of their unique abilities. For instance, they can help to improve bioavailability
of hydrophobic drugs, in vivo stability, or controlled drug release.28 Similar to liposomes,
micelles/polymeric micelles also possess a vesicular structure. However, they consist of only one
monolayer of amphiphilic molecules in contrast to liposomes with bilayers. Formation of such
micelles requires the critical micelle concentration (CMC), above which monomeric amphiphile
can undergo self-assembly to form micelles.29-30 Traditional micelles consist of a hydrophilic
shell and a hydrophobic core, which are generally formed by the heads and the fatty acid tails of
phospholipids, respectively. Polymeric micelles also display a core-shell structure as a result of
assembly of block copolymers. Formation of these polymeric micelles can be achieved at lower
CMC as compared to that of traditional micelles, resulting in enhanced aqueous stability and
extended drug release.30 Many studies have demonstrated great potential of polymeric micelles
as a powerful tool for cancer therapy. Several anticancer drugs such as NK911, NK105, and
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Genexol-PM formulated by use of polymeric micelles have already been approved for clinical
trials to treat solid tumors. 31
Dendrimers are identified as a class of nanosized synthetic macromolecules that have a
well-defined, hyper branched, and tree-like structure. A dendrimer is typically composed of three
topological parts including a central core, an inner shell, and an outer shell. The central core is
either a central atom or groups of atoms. The inner shell is formed from the central core with
radical growth of branches of other atoms via chemical reactions. At the end of these branches,
the chemical functional groups construct the outer shell of these macromolecules. Such unique
structure allows to prepare various host-guest complexes through multivalent interactions, thus
providing many advantages of dendrimers for drug delivery.32 Dendrimers have shown good
capabilities to deliver both hydrophobic and hydrophilic drugs using either encapsulation or
conjugation mechanism. In this context, hydrophobic drugs are encapsulated into the
hydrophobic core, while hydrophilic drugs are covalently conjugated with functional groups on
the surface of dendrimers.33-34 As compared to other nanocarriers with either non-defined or
limited structural diversity, dendrimers display a well-defined structure with polyvalency, which
enables conjugation with several drug molecules, targeting moieties, and solubilizing groups at
the surface of the dendrimers.35 In this regard, dendrimers can provide more possibilities to
achieve controlled drug release and identifications of specific targets for cancer therapy. For
example, Patri et al. reported a study regarding the use of folic acid conjugated PAMAM
dendrimer for targeted delivery of methotrexate. This study demonstrated high specificity for
receptor-expressing cells and controlled drug release by using dendrimer as the drug carrier.34
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Figure 1.2. Basic structures of nanoparticles discussed in this dissertation.
1.2.2. Carrier-free Nanodrugs for Cancer Treatment
The above-mentioned nanomaterials have been primarily investigated as drug carriers to
improve cancer treatment. They all display several promising properties; however, several
challenges also arise with these nanocarriers. These concerns accrue from several potential issues
such as complexity of fabrication, limited drug loading, and carrier-induced systemic toxicity, all
of which limit their further applications for cancer treatment.36-38 To address these issues, many
efforts have been made to develop carrier-free nanodrugs.37,

39-40

Carrier-free nanodrugs are

typically synthesized through self-assembly of the therapeutic drug without introducing any
additional materials. In this regard, therapeutic efficacy of drugs is improved, while materialrelated toxicity is eliminated. In addition, using carrier-free nanodrugs for combinational therapy
has been extensively investigated to further improve therapeutic effects for cancer treatment. In
this scenario, nanodrugs have the capability to use several different anticancer mechanisms to
simultaneously kill cancer cells, resulting in a synergetic therapeutic efficacy. For example,
Zhang and co-workers reported a carrier-free nanodrug that incorporates both doxorubicin (DOX)
and chlorin e6 (Ce6) via co-assembly. As a result, such all-in-one nanodrug exhibited a
synergetic antitumor effect in vivo by combining chemotherapy (DOX) and photodynamic
therapy (Ce6) in a single treatment.41 Another study from Zhao et al. demonstrated a HD
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nanodrug that was prepared by co-assembly of two chemotherapeutic drugs including 10hydroxycamptothecin (HCPT) and DOX. It was concluded that such dual nanoparticles can
effectively inhibit drug-resistant cancer cells due to a synergetic anticancer effect.42
In this regard, a group of uniform materials based on organic salts (GUMBOS) have been
developed in our research group for application in cancer therapeutics.43 These GUMBOS are
easy to synthesize via a simple ion exchange reaction. By varying counter-ions in GUMBOS, a
broad tunability can be achieved with respect to their melting point, hydrophobicity, solubility,
thermal stability, and toxicity.44 Therefore, using GUMBOS concept can be a promising strategy
to prepare nanodrugs for combination therapy. In this scenario, GUMBOS can be designed by
incorporation of cations and anions with inherent therapeutic properties, followed by direct
conversion into nanoGUMBOS as nanodrug to achieve efficient therapeutic efficacy. In this
dissertation, development of a series of near infrared (NIR) IR780-based nanoGUMBOS for
cancer treatment is discussed.
1.3. Multi-functional NIRF Heptamethine Dyes
A class of near infrared fluorescent (NIRF) heptamethine dyes have recently been
investigated as theranostic agents for cancer therapy. Such agents are characterized as
multifunctional materials that combine both imaging and therapeutic functionalities in a single
dose. These dyes are heterocyclic polymethine cyanines such as IR780, IR808, IR813, and MHI148.45 Structures are shown in Figure 1.3. They all have shown strong absorptivity and intense
fluorescence in the NIR range of 700 nm to 900 nm, which is known as the transparent window
of tissues, thus enabling strong imaging potential of these dyes. Many studies have also
demonstrated promising characteristics of these heptamethine dyes as photosensitizers that can
generate heat or reactive oxygen species (ROS) upon NIR irradiation.46-48 Such unique properties
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have prompted development of these NIR heptamethine dyes for applications in imaging,
photothermal therapy (PTT), and photodynamic therapy (PDT). Among them, IR780 has been
recognized a prototypic NIR heptamethine agent that possesses unique optical and therapeutic
features. It is also identified as the first inherently mitochondria targeting NIRF dye because of
its unique structure (Figure 1.3).49 Since the mitochondria play an important role in energy
metabolism and cell cycle, various mitochondria-targeted approaches for cancer therapy are
being tested in clinical trials.50 In this regard, many extensive studies of IR780 have been
performed in recent years to explore its potential use for biomedical applications.49, 51-53
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Figure 1.3. Chemical structures of various heptamethine dyes.
1.3.1. NIRF Imaging Application of IR780
In recent years, NIRF imaging has been widely employed for cancer diagnosis. As an
optical imaging technique, it has several distinct advantages over other imaging techniques such
as high sensitivity, time saving, and multi-detection capability.54-55 Furthermore, NIRF imaging
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technique possesses low autofluorescence, absorbance, and scattering, all of which make it very
sensitive for in vivo studies.56 Most importantly, using NIRF imaging for cancer therapy allows
for real-time monitoring of in vivo therapeutic responses due to its excellent spatial and temporal
resolution. In this context, the administration of a specific NIRF agent that can emit strong
fluorescence in the NIR window is made in advance. The most commonly used NIRF probe is
the FDA approved indocyanine green (ICG). However, several disadvantages of ICG incluidng
low quantum yield, a lack of tumor targeting, and fast clearance within minutes lead to a lack of
applicability of ICG in tumor tracking and long-term imaging applications.52, 54, 57 Thus, it is
necessary to develop an alternative NIRF probe that can address these above-mentioned issues
for precise NIRF based diagnostic applications.
Recently, a NIRF heptamethine agent IR780, was developed. It is a lipophilic cationic
dye that shows a preferential tumor accumulation in several tumor-xenograft models without use
of any targeting moiety.52, 58-59 The mechanism for such tumor targeting behavior was revealed to
be associated with the organic anion transporting polypeptides (OATPs) that are overexpressed
in cancer cells.51, 59 In addition to the intrinsic targeting property, IR780 has also shown better
photo-stability and stronger fluorescence in the NIR region as compared to ICG, making it a
strong candidate for tumor targeting imaging. Many studies reported the use of IR780 for in vivo
imaging. For example, Zhang et al. demonstrated the successful detection of breast, cervical,
lung and osteosarcoma tumors in mice using IR780 as NIRF imaging probe.59 In another study,
Yi et al. investigated the application of IR780 for prostate cancer detection. They concluded that
NIRF imaging using IR780 dye can selectively identify prostate cancer both in vitro and in vivo,
suggesting a sensitive and noninvasive imaging technique for future cancer detection.51
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1.3.2. Therapeutic Applications of IR780: Chemotherapy, PTT and PDT
As a lipophilic cation, IR780 was shown to primarily target the mitochondria of cancer
cells, which is characterized with a highly negative membrane potential.60-61 The
chemotherapeutic effects of IR780 arise from its capability to deregulate mitochondrial functions
in cancer cells at a high dose of administration, ultimately leading to cell apoptosis. As indicated
in a previous study, treatment of IR780 on drug-resistant lung cancer cells led to a significantly
increased ROS production, decreased mitochondrial membrane potential, and subsequently a
large amount of apoptosis. Furthermore, this study also demonstrated remarkable tumor killing
activities and tumor recurrence inhibition of IR780 in vivo, suggesting its chemotherapeutic
application.62
In addition to chemotherapeutic applications, IR780 has been used for cancer
phototherapies such as PTT and PDT.63-64 These novel phototherapies possess several distinct
advantages over traditional cancer treatments such as radiotherapy and chemotherapy, making
them strong alternatives for cancer treatments in recent years. These advantages include high
specificity, minor invasiveness, remarkable therapeutic efficacy, and minimal drug resistance.65
Using this NIR dye for phototherapy can further enhance in vivo therapeutic efficiency of PTT or
PDT due to the deep tissue penetration of NIR light. In PTT, IR780 serves as a photothermal
agent that has a strong capability to produce a temperature increase upon interactions with NIR
light, resulting in tumor ablation (Figure 1.4). In this context, IR780 is excited by NIR light to
the excited singlet state, where energy is subsequently released in the form of heat via vibrational
relaxation or other non-radiactive transitions. The high efficiency of heat production then causes
a gradual temperature increase, ultimately leading to hyperthermia that destroys cancer cells. As
for PDT, IR780 is employed as a photosensitizer that can produce highly toxic ROS species
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towards tumor cells with NIR light irradiation (Figure 1.4). In this case, following excitation of
IR780, an energy transition from the excited singlet state to the more stable excited triplet state
occurs via intersystem crossing. Subsequently, this excited triplet state decays to the ground state,
while reacting with the nearby biological environment, thus leading to generation of ROS species
including free radicals and singlet oxygen (1O2 ). As compared to several NIR dyes such as ICG,
a superior quantum yield of 1O2 by IR780 has been detected.52 Overall, the unique NIR optical
properties, tumor targeting capacity, and highly efficient photothermal and photodynamic
activities of IR780 indicate a strong potential for its future applications in PTT and PDT.
Despite these promising therapeutic properties, the direct application of IR780 for
chemotherapy, PTT and PDT remains hindered due to several disadvantages including
lipophilicity, photobleaching, fast clearance, and low dose tolerance.52 To overcome these
deficiencies, various nanomaterials have been developed and served as nanocarriers to deliver
lipophilic IR780 to tumor sites via passive or active targeting mechanisms. These nanocarriers
include micelles,66-67 liposomes,63,

68

and proteins,64,

69

. By encapsulation of IR780 in these

nanocarriers, the solubility of IR780 was significantly improved. For instance, Pais-Silva et al.
reported a 105- to 115- fold increase in the solubility of IR780 after being loaded into the TPGSTOS micelle.66 Additionally, incorporation of IR780 in phospholipid micelles resulted in an
enhanced tumor accumulation in the U87MG glioma ectopic and orthotopic xenograft model due
to the EPR effect.68 However, as discussed previously in this chapter, many concerns and
limitations also exist when nanocarriers are used. Herein, given that IR780 is a superior ionic
material, this dissertation will focus on using GUMBOS and nanoGUMBOS as alternative
approach to promote future therapeutic application of IR780.
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Figure 1.4. Schematic illustration of IR780 for PTT and PDT applications.
1.4. Ionic Materials
1.4.1. Ionic Liquids
Ionic liquids (ILs) are a class of organic salts that consist entirely of ions with a melting
point below 100 oC.44, 70 The synthesis of ILs typically involves use of a large organic ion and a
small inorganic or organic counter-ion, resulting in asymmetric packing and thus a reduced
melting point. Therefore, using different combinations of various cations and anions, these
organic salts can either be liquids referred to as room temperature ionic liquids (RTILs), or solids
referred to as frozen ionic liquids (FILs). RTILs have a melting point below 25 oC, and are
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widely used as green solvents for substitution of most volatile organic solvents,71 while FILs are
solid-phase organic salts that have a melting point range from 25 oC to 100 oC.
The first IL was discovered by Paul Walden in 1914 regarding the compound
ethylammonium nitrate that has a melting point of 12 oC.72 Despite the long history, ILs have
only received attentions in the last two decades. As reported, the number of publications
regarding ILs have displayed an exponential increase from a few in 1996 to more than 5000 in
2016.70 Applications of ILs have been widely explored in synthesis, catalysis, separations,
electrochemistry, sensing, and pharmaceutics. Overall, the development of ILs has been
classified into three generations based on their properties (Figure 1.5).73-74 The first generation of
ILs is mainly constituted by cationic dialkylimidazolium or alkylpyridinium derivatives and
anionic chloroaluminate or other metal halides. Although these ILs display unique physical
properties such as high thermal stability and low vapor pressure, they are sensitive towards water
and air. Second generation ILs have shown improved water- and air- stability by replacing the
reactive anion with other anions such as BF4-, PF6- and C6H5CO2-. These ILs have many
interesting tunable physical and chemical properties by modifying the counter-ion, which make
them promising functional materials for various applications. It has been reported that many
RTILs have been used as reaction media to improve several organic syntheses.74-75 Finally, taskspecific ILs have been introduced by Davis as the third generation of ILs, which contain more
biodegradable and less toxic ions in comparison with the first two generations.76 This generation
focuses on use of biologically active ions to produce ILs, extending applications of ILs in
pharmacy and medicine.73 This dissertation will explore use of GUMBOS similar to thirdgeneration ILs for biomedical applications.

14

1st generation
N

• ILs with tunable physical properties
• Water and air sensitive

N+

R1

R2

N+

AlCl4-

FeCl4-

R

2nd generation
R3

N

N+

R1

R3

R2 R4

R1

R2

• ILs with targeted chemical properties
with chosen physical properties
• Water- and air- stable

N+

F
F

F

F

P-

N+
R4

R1
P+

R2

F

R

F

B-

F
F

F

F

3rd generation
N+

14

N+

OH
COO-

O

O
S

NH2

CH2

COO-

N-

OH

• ILs with targeted biological properties
with chosen physical and chemical
properties
• Low toxicity
• High biodegradability

O

Figure 1.5. The evolution of ILs from unique physical properties to chemical and biological
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1.4.2. GUMBOS
In recent years, a group of uniform materials based on organic salts termed GUMBOS
have been developed in the Warner Research Group, reflecting on the versatility of ILs.44
GUMBOS are solid-phase organic salts that consist of bulky organic or inorganic counter-ions.
These compounds have a defined melting point range of 25 oC to 250 oC, in comparison with ILs
which have melting point below 100 oC. In terms of counter-ions used, GUMBOS are similar to
ILs, displaying broad tunable properties with counter-ion variation. These tunable properties
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include, but are not limited to, melting point, hydrophobicity, solubility, polarity, optical
behaviors, and toxicity. Furthermore, the flexibility of IL chemistry allows design of GUMBOS
to serve as task-specific as well as multi-functional materials, resulting in a variety of
applications such as cancer therapy, sensing, imaging, energy storage, and optoelectric devices.
For instance, Bwambok. et al reported a study regarding the use of a given near infrared
fluorescent (NIRF) imaging dye, HMT, to synthesize [HMT][AOT]GUMBOS for biomedical
imaging.77 These GUMBOS displayed excellent NIR fluorescence, allowing for potential NIRF
imaging application in vivo. In another study, Magut. et al. developed several rhodamine 6G
based GUMBOS and nanoGUMBOS for chemotherapeutic applications.78 Interestingly, tunable
chemotherapeutic properties of these nanoGUMBOS were observed upon counter-anion
variation. Moreover, Cole et al. demonstrated an antimicrobial application of GUMBOS that
consist of both antibiotic and antiseptic counter-ions. Such combination into a single GUMBOS
resulted in a synergist effect to combat multidrug resistant bacteria.79 Therefore, using a similar
approach, GUMBOS can also be designed and applied for combination therapy by use of two
therapeutic ions with different anticancer mechanisms.
1.4.3. Synthesis of GUMBOS
An added advantage of using GUMBOS for various applications is the simplicity of
synthesis of GUMBOS from ionic compounds. Typically, the synthesis involves only a singlestep ion exchange methathesis reaction when starting materials are salts. Two examples are
discussed in Figures 1.6 and 1.7. The first example depicts an ion exchange reaction between
rhodamine 6G ([R6G][Cl]) and lithium bis(perfluoroethylsulonyl)imide ([Li][BETI] in a
biphasic system, e.g. dichloromethane (DCM)/ water (Figure 1.6). This system is usually used
when one of the ionic reactants is water soluble while another one is water insoluble. Briefly,
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[R6G][Cl] and [Li][BETI] are dissolved in a mixture of DCM/water with a 2 to 1 volume ratio,
and subsequent stirred for 24 h at room temperature. Finally, [R6G][BETI] GUMBOS are
isolated from the organic phase, and byproducts are removed after several washes of water.43
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Figure 1.6. Two-phase reaction for preparation of R6G GUMBOS.
The second example represents a reaction to prepare hydrophobic [Hmim][TPB]
GUMBOS in a one phase medium, e.g. water (Figure 1.7). In this scenario, both starting
materials

including

1-hexyl-3-methylimidazolium

chloride

([Hmim][Cl])

and

sodium

tetraphenylborate ([Na][TPB]) are dissolved in water for anion exchange. The resultant
GUMBOS precipitated out and were collected after centrifugation and several washes of water.80
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Figure 1.7. One-phase reaction for preparation of [Hmim][TPB] GUMBOS.
1.4.4. NanoGUMBOS
NanoGUMBOS are nanomaterials derived from GUMBOS, which have the versatility of
GUMBOS. Meanwhile, nanoGUMBOS possess enhanced physicochemical properties at the
nanoscale level as compared to GUMBOS, further expanding their applications. Notably,
conversion of hydrophobic anticancer GUMBOS into nanoGUMBOS can provide several
distinct advantages for therapeutic applications.43 For example, using nanoGUMBOS as a
therapeutic agent can eliminate the use of organic solvent, thus reducing any solvent-related
toxicity. Also, the bioavailability of anticancer agents can be significantly enhanced due to the
small size and large surface area of nanoGUMBOS. Meanwhile, passive tumor targeting can be
achieved by taking advangtages of the EPR effect when nanoGUMBOS are used . In addition,
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tunable properties of nanoGUMBOS arising from GUMBOS allow for easy modification to
overcome the emerging drug resistance from chemotherapy. Most importantly, the ease of
synthesis of these nanoGUMBOS enables rapid development of novel carrier-free nanodrugs
without introduction of drug carrier materials, thus minimizing material-related toxicity.
1.4.5. Synthesis of NanoGUMBOS
Using hydrophobic properties of GUMBOS, nanoGUMBOS can be rapidly formed
through self-assembly in an aqueous system. In this dissertation, a reprecipitation method with
the assistance of ultrasonication was primarily used to produce the desired nanoGUMBOS
(Figure 1.8).81 This method involves use of two miscible solvents, and the sample is only soluble
in one of the solvents. Herein, organic solvents (e.g. acetone, or DMSO) are used for solubilizing
hydrophobic GUMBOS. Subsequently, a rapid injection of small aliquots of GUMBOS into a
large amount of non-solvent system (e.g. cell medium or water) is performed under
ultrasonication. In this context, the hydrophobic GUMBOS initiate self-assembly and precipitate
at the cavitation sites created by ultrasonication into nanoGUMBOS. Using this method,
spherical nanoGUMBOS are generally obtained. In addition, the size and uniformity can be
readily tailored by variation in the initial concentration of GUMBOS, volume ratio of two
miscible solvents, and the power of ultrasonication, as demonstrated in previous literature.80
nanoGUMBOS
GUMBOS solution

sonication

water

nanoGUMBOS

500 nm

TEM

Figure 1 8. Reprecipitation method for preparation of nanoGUMBOS.
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1.5. Analytical Methods
1.5.1. Ultraviolet-visible Absorption Spectroscopy
Ultraviolet-visible spectroscopy (UV-Vis) is a powerful analytical technique for
characterization and quantitative determination of molecules that absorb light in the UV or Vis
region of the electromagnetic spectrum.82 In physical terms, light is considered as
electromagnetic radiation, a form of energy, that is transmitted through space at enormous
velocities. When sample molecules are exposed to light, such energy can be absorbed and
transferred to the molecules in form of photons or quanta. As a result, the analyte at the ground
state undergoes a transition to the excited state. In absorption spectroscopy, the amount of light
absorbed as function of wavelength is measured, which is defined as absorbance (A). The
absorbance can be correlated to the concentration of sample (c), molar absorptivity (e), and path
length of the cuvette (b) using Beer-Lambert’s Law expressed in Equation 1.1.83
A = εbc

1.1

The schematic diagram of a typical UV-Vis spectrophotometer is shown in Figure 1.9.
The major components include a light source, a monochromator, sample and reference holders,
and a detector. A typical light source is a combination of deuterium and tungsten lamps that
cover the entire UV-Vis region. The generated energy from the lamp is passed through a
monochromator that selects the wavelength of interest. Subsequently, the filtered light is divided
into two beams of light by a beam splitter, which are passed through the reference and sample
cells, respectively. The intensity of transmitted light at different wavelengths is then measured by
a detector, and further correlated to absorbance.
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Figure 1.9. Schematic of a UV-Vis spectrometer.
1.5.2. Fluorescence Spectroscopy
Fluorescence spectroscopy is commonly used to analyze fluorescence from a sample that
absorbs light in the electromagnetic spectrum. It is a highly sensitive and specific tool for various
applications.84-85 Fluorescence is a photoluminescent process in which molecules at the ground
state (S0) are excited by absorption of light, followed by rapid decay from the lowest excited
singlet state (S1) to S0 with emission of light. This process occurs over few nanoseconds.
Molecules that fluoresce are called fluorophore. Another type of photoluminescence is referred
to as phosphorescence, in which emission results from the transition from excited triplet state T1
to S0. However, the probability of such process is small, resulting in a long lifetime of
phosphorescence from few milliseconds to seconds. In addition to phosphorescence, other
processes also compete with fluorescence; such as, internal conversion and intersystem crossing.
These two processes are non-radiative transitions and also have unique characteristics. Internal
conversion occurs from a higher electronic state to a lower electronic state of same multiplicity,
i.e. S2 to S1, which is also responsible for the fluorescence emission wavelength being longer
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than the absorption wavelength. This shift to a longer wavelength is a phenomenon known as the
Stokes shift.84 In contrast, intersystem crossing describes a transition between the excited
electronic states of different multiplicity, i.e. S1 to T1. It is a process that reduces fluorescence
signals but promotes the generation of phosphorescence. All these processes are illustrated using
a Jablonksi diagram (Figure 1.10).83, 86

S2
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Absorption
Intersystem crossing
S1

T1

Fluorescence

Phosphorescence

2
1

S0

0

Figure 1.10. Jablonksi diagram showing the electronic states and possible transitions between
different singlet and triplet states.
A typical diagram of a spectrofluorometer is shown in Figure 1.11. In general, the light
generated from a lamp source travels through an excitation monochromator that selects a desired
excitation wavelength to excite the sample. The fluorescence emitted by the sample is then
collected after passing through an emission monochromator perpendicular to the incident beam.
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Using such an instrument, fluorescence intensity, spectrum, lifetime, as well as polarization are
generally measured, providing a sensitive method to study biological structures and functions
using a fluorescent probe.87-88

Excitation
monochromator

Sample

Emission
monochromator

Light source
Detector
Figure 1.11. Schematic representation of a typical spectrofluorometer.
1.5.3. Fluorescence Microscopy
Fluorescence microscopy integrates optical microscopy with the fluorescence concept.
Such a combination provides both spatial and temporal analysis of various chemical species in
the biological system, making fluorescence microscopy an attractive tool for biological studies.
These studies include but are not limited to direct visualization of molecular targeting,
interactions, and dynamics in cells and organisms.85 In this dissertation, visualization of cellular
uptake and subcellular localization of nanoGUMBOS within cells were examined by use of
fluorescence microscopy. Figure 1.12 displays a representative schematic of a basic fluorescence
microscope. Majority of components are similar to those of a spectrofluorometer such as light
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source, excitation and emission filters, and the detector. Considering the upright geometry of the
microscope, most fluorescence microscopes are also equipped with dichromatic mirrors, which
typically reflect shorter wavelengths but allow longer wavelengths to pass through. In this
context, the filtered excitation light is reflected by the dichromatic mirror, allowing excitation of
the fluorophores in the sample at 90o angle. The emitted fluorescence by fluorophores is then
detected by a camera after passing through the dichromatic mirror and the emission filter. 89
Ocular
v

Switchable mirror
CCD camera

Emission filter
Excitation filter

Dichroic mirror

Light source

objective

Sample

Figure 1.12. Schematic representation of a fluorescence microscope.
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1.5.4. Transmission Electron Microscopy
Transmission electron microscopy（TEM）is a powerful imaging technique that has
been widely applied for material science.90 This technique adopts the same basic principles as the
optical microscopy; however, TEM uses electrons that have a much smaller wavelength than
light for magnification.91 In this regard, the obtained TEM images have superior resolution with
many orders of magnitude better than these images generated from a light microscope.92 Such
high resolution from TEM imaging allows a very detailed characterization of structures at
nanoscale.
The schematic of a TEM microscope is illustrated in Figure 1.13. Briefly, the electron
gun generates a beam of electrons that are subsequently focused into a small and coherent beam
by passing through condenser lens. The focused beam then strike the sample, resulting in
scattering and transmission of electrons depending upon the thickness and electron transparency
of the prepared sample. Afterwards, the transmitted electrons pass through a series of
electromagnetic lens that help to focus electrons onto a fluorescent screen for generating an
image. The image is then captured using a charge coupled device (CCD) camera. This whole
process takes place in a vacuum chamber for two reasons. One is to prevent electrons from
interactions with air molecules in the microscope, thus minimizing scattering of electrons.
Another reason for incorporation of the vacuum system in the TEM microscope is to prevent
contaminations that are created by interactions of electrons and residual gas molecules. 93-94
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Figure 1.13. Schematic diagram of a TEM microscope in a vacuum chamber.
1.5.5. Dynamic Light Scattering
Dynamic light scattering (DLS) is a characterization technique that is commonly used for
particle size analysis of various systems such as proteins, micelles, emulsions, and
nanoparticles.95-97 This technique measures fluctuations in the intensity of scattered light caused
by the Brownian motion of particles in solution. Briefly, a laser beam is used to illuminate the
particle solution, resulting in light scattering. Due to the Brownian motion of particles in a
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random and constant manner, the intensity of scattered light fluctuates as a function of time.
These time-dependent fluctuations are then measured by a fast photon counter and analyzed
using an autocorrelation function, generally expressed in Equation 1.2:
G t = < I t .I t + t >

1.2

where t is the time delay.
For monodispersed samples, this function is typically an exponential decaying function of time
delay. Since small particles generally display a fast Brownian motion, a rapid decay of the
scattered light is observed. In contrast, large particles move slowly in solution, resulting in a long
decay. Therefore, using the decay of the correlation function, the velocity of Brownian motion
defined as diffusion coefficient (D) can be determined based on assumptions of spherical shape,
low concentration, and the known viscosity of dispersing medium. Ultimately, the particle
hydrodynamic size is calculated from D by using the Stokes-Einstein equation98:
𝑑 𝐻 =

𝐾3 𝑇
3𝜋𝜂𝐷

1.3

where 𝑑(𝐻) is hydrodynamic diameter of the particle, 𝐾3 is the Boltzmann constant, T is the
absolute tempearature, 𝜂 is the viscosity, and D is the diffusion coefficient.
Using DLS for nanoparticle characterizations provides many advantages including easy
operation, rapid analysis, high sensitivity and reproducibility.99 However, certain disadvantages
are also present. For example, an inaccurate result may be obtained when sample is highly
polydispersed. Furthermore, DLS is only suitable for spherical shaped nanoparticles.99-101 In this
dissertation, DLS has been used to study the hydrodynamic size and aqueous stability of
spherical nanoGUMBOS, which can help to predicate the suitability of nanoGUMBOS for
further in vitro or in vivo studies.
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1.5.6. Zeta Potential Analysis
Zeta potential (z) is an important parameter for evaluation of stability of nanoparticle in
solution.102 It is a measure of surface charge that develops at the interfacial layer between the
nanoparticle and the dispersant. This interfacial layer is also defined as electrical double layer
consisting of two parts including a stern layer and a diffuse layer (Figure 1.14). The stern layer is
the inner region where ions are strongly bound to the particle surface. The diffuse layer is the
outer region where ions are less tightly associated to the particles. In addition, the diffuse layer
possesses a notional boundary known as slipping plane, inside which ions stay with the particle
as a stable entity. However, beyond the slipping plane, ions are not attached to the particle and
are considered as bulk dispersant. Zeta potential is the potential at this slipping plane. To
determine zeta potential of particles, Laser Doppler Electrophoresis is used to measure
electrophoretic mobility(µ), which is then correlated to the zeta potential using the Henry
equation:103
µ=

2ζε
f Ka
3η

1.4

Where ε is the electric constant, ζ is the zeta potential, η is the viscosity of dispersant, and f(Ka)
is Henry’s function (generally 1 or 1.5).
Theoretically, the magnitude of zeta potential is dependent on the degree of electrostatic
repulsions between adjacent particles that are similarly charged in solution. In general,
nanoparticles with low zeta potential tend to aggregate in solution since attractive forces exceed
repulsive forces. In contrast, repulsions of nanoparticles with high zeta potential are stronger
than the attractive forces, leading to formation of a stable system.104 It has been assumed that
nanoparticle are electrostatically stable when a magnitude of zeta potential is greater than 30
mV.105
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Figure 1.14. Schematic representation of zeta potential.
1.5.7. Cell Viability Assay
In vitro cell viability assays have been widely employed for oncological researches.
During drug development, these assays can provide rapid, inexpensive and even automated
evaluation of in vitro cytotoxic effects of a great number of compounds using human cells.
Typically, these cell viability assays measure some of the cell functions as an indicator of viable
cells; such as, metabolism, enzyme activity, or cell adherence etc.106 In this dissertation study, a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) reduction assay has been used to
assess cytotoxicity of all nanoGUMBOS in vitro. It is a colorimetric assay with easy procedures
and high reproducibility.107-108 This assay is primarily based on evaluation of activities of the
mitochondrial enzymes. In this assay, only viable cells with the active enzymes can reduce MTT
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compound into a purple formazan crystal with a peak absorbance at 570 nm (Figure 1.15),109
while dead cells lack of the capability of this reduction. Therefore, the number of viable cells are
presumably proportional to the absorbance of formazan products. In addition, the detected
absorbance using this assay are not only determined by the number of viable cells, but also
affected by several other parameters such as concentration and incubation time of MTT.110 Thus,
optimization of the assay conditions is typically performed prior to use for quantifying viable
cells using absorbance measurements.
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Figure 1.15. Reduction reaction of MTT into formazan in viable cells.
1.6. Scope of Dissertation
The primary goal of this dissertation is to develop multi-functional GUMBOS and
nanoGUMBOS for biomedical applications including chemotherapy, chemo/photothermal
therapy, and drug delivery. In Chapter 2, a series of IR780 based GUMBOS and nanoGUMBOS
were developed and examined as potential chemotherapeutic agents. These GUMBOS displayed
tunable physicochemical properties wtih counter-ion variation. Interestingly, examination of in
vitro cytotoxicity of nanoGUMBOS using both normal and cancer cells indicated an enhanced
selective toxicity towards cancer cells upon counter-ion exchange with the parent compound.81
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Chapter 3 highlights the use of a cyclodextrin complexing approach to synthesize tumor
targeting

NIR

nanoGUMBOS

for

chemo/photothermal

therapy.

Optimization

and

characterizations of these nanoparticles are presented. In addition, both experimental and
computational approaches are performed to study the complexation mechanism for nanoparticle
formation. In vitro cytotoxicity with and without laser irradiation were also examined to study
chemo/photothermal therapeutic effects of the synthesized nanoparticles. Finally, in vivo tumor
targeting behavior of these nanoparticles were investigated using NIRF imaging and the
antitumor efficacy of chemo/photothermal treatment was evaluated using an MDA-MB-231
tumor xenograft mouse model. In Chapter 4, a group of PEGylated nanoGUMBOS with different
counter-anions were developed as drug carriers for delivery of a hydrophobic anticancer drug,
paclitaxel. The detailed synthesis and characterizations of these nanoGUMBOS are outlined.
Drug loading and drug release behaviors of these nanoGUMBOS were also evaluated and
discussed. Finally, in vitro study was performed using several breast cancer cell lines to examine
the chemotherapeutic effects of paclitaxel by using these nanoGUMBOS as drug carriers.
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CHAPTER 2. MITOCHONDRIA TARGETING IR780-BASED NANOGUMOBS FOR
ENHANCED SELECTIVE TOXICITY TOWARDS CANCER CELLS*
2.1. Introduction
Cancer remains a leading cause of death worldwide.1 Much effort has been devoted
toward development of novel therapeutics for highly effective cancer therapy.2-4 Chemotherapy,
one of the most common and efficient cancer treatments, has provided considerable progress
over the past few decades. However, many issues such as drug resistance and systemic toxicity
arise with use of conventional chemotherapeutics.5-6 Many mechanisms can be identified for
drug resistance including enhanced DNA repair, decreased drug activation, and increased drug
degradation.7 The latter systemic toxicity can be attributed to lack of selective toxicity of most
chemotherapeutic drugs due to non-targeted distribution through the body. This problem
ultimately leads to destruction of much of the body’s healthy tissue along with treatment of the
tumor.2-4 Therefore, it is essential to develop more efficient and selective chemotherapeutics for
cancer treatments.
Mitochondria are special subcellular organelles that serve as the main powerhouse of cell.
They play a significant role in regulation of cellular metabolism, calcium homeostasis, and
programmed cell death.8 Importantly, cancer cells have a more hyperpolarized mitochondrial
membrane potential (ΔΨm) in comparison with normal cells, which makes the uptake of cationic
drugs into the cancer cells more favorable.9 As a result, targeting of mitochondria has emerged as
an attractive strategy for efficient and selective cancer chemotherapy.10-11 Recently, a lipophilic
near-infrared (NIR) heptamethine dye, IR780, has been shown to have promising anticancer
*

Reproduced from Chen, M.; Bhattarai, N.; Cong, M.; Pérez, R. L.; McDonough, K. C.; Warner,
I. M., Mitochondria targeting IR780-based nanoGUMBOS for enhanced selective toxicity
towards cancer cells. RSC Adv. 2018, 8 (55), 31700. DOI: 10.1039/C8RA05484C with
permission from the Royal Society of Chemistry.
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characteristics that acts on mitochondria. Free IR780 has been shown to be internalized through
organic anion transporter polypeptides (OATPs), and thus cause mitochondrial dysfunction,
ultimately inducing cell apoptosis.12-13 Despite the anticancer characteristics of this cationic dye,
very little research has focused on the application of IR780 as a possible chemotherapeutic agent.
Since IR780 has intense fluorescence under NIR excitation, it has primarily been used as a
theranostic agent for cell imaging, photodynamic therapy (PDT), and photothermal therapy
(PTT).14-20 However, low bioavailability and non-selective toxicity at high concentrations have
limited its further biological applications.18 To address these issues, various nanoscale delivery
systems have been developed to encapsulate IR780 in order to minimize systemic toxicity
through passive targeting mechanisms such as enhanced permeability and retention effect (EPR).
These delivery systems involve use of micelles, polymeric nanoparticles, or quantum dots.14-20
However, there are several challenges when using nanoscale drug carriers, including complexity
of nanoparticle fabrication, limited drug-loading, and difficulties in controlled drug release at the
tumor site.14, 16-19, 21 In this regard, a new concept of carrier-free nanodrugs has been reported,
which involves fabrication of nanomaterials using the anticancer drug itself as a
chemotherapeutic material and without introduction of drug carrier materials.2, 5-6 For example,
hydrophobic drug molecules can undergo self-assembly to form nanodrugs via change from
organic solvent to a non-solvent system, such as aqueous solution.22-23 Several nanodrugs have
already been approved for clinical trial due to the ultra-high drug loading and reduced materialrelated toxicity of this approach.24 In order to promote the wide application of nanodrugs for
clinical cancer therapy, it is highly desirable to design nanodrugs with easy synthesis, good
physiological stability, and highly selective toxicity towards cancer cells relative to normal cells.
In recent years, a group of uniform materials based on organic salts (GUMBOS) has been
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developed in our laboratory for several biomedical applications.2, 25-27 Although similar to ionic
liquids in terms of counter-ions used, GUMBOS are solid-phase analogs with a defined melting
point range of 25 °C to 250 °C. Such organic salts are found to have broadly tunable properties
such as toxicity, hydrophobicity, melting point, and optical behaviors.2,

25-26, 28-29

Thus,

GUMBOS can be designed for specific tasks through simple counter-ion variations.
Nanoparticles derived from these GUMBOS (nanoGUMBOS) generally display enhanced,
unique, and tunable properties at the nanoscale level as compared to GUMBOS. Specifically,
conversion of hydrophobic GUMBOS into nanoGUMBOS for therapeutic applications can
enhance bioavailability of therapeutic agents due to the small size and large surface area of
nanoGUMBOS. It has also been acknowledged that nanoparticles aid in achieving passive tumor
targeting due to the EPR effect of the nanoscale size, which can make nanoGUMBOS more
favorable as potential chemotherapeutic drugs in comparison with GUMBOS.30 Furthermore, the
ease of synthesis of such nanoGUMBOS allows for development of a novel carrier-free
nanodrug without addition of other matrices.
In this present study, I aim to enhance the selective cytotoxicity of IR780 for future
chemotherapeutic applications through conversion to GUMBOS and nanoGUMBOS. By use of
certain advantages of the nanodrug, as well as the GUMBOS concept, I have fabricated a series
of IR780-based GUMBOS ([IR780][Asc], [IR780][OTf], [IR780][BETI]) through anionexchange of [IR780][I] with various bulky organic counter-anions. These selected anions have
varying compositions, size, and hydrophobic properties. Additionally, no cytotoxicity towards
cancer or normal cells has been observed for these anions under studied conditions.2
Characterization of these GUMBOS by use of parameters such as hydrophobicity, melting point,
absorption, and fluorescence properties was performed. Quasi-spherical nanoGUMBOS were
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then obtained by directly nanoengineering these GUMBOS using an ultrasonication-assisted
reprecipitation method, which has been previously described.2, 23, 25-26, 31 These nanomaterials
were then tested in vitro using both cancer cells and normal cells to study drug efficacy.
Examination of results from these studies indicate that these novel NIR nanomaterials provide
unique properties for future in vivo chemotherapeutic applications.
2.2. Materials and Methods
2.2.1. Materials
IR780 iodide (98%), trifluoromethanesulfonate (OTf) sodium salt (98%), sodium Lascorbate (98%) (Asc), dichloromethane (DCM), chloroform, methanol, and anhydrous
acetonitrile were purchased from Sigma Aldrich and used as received. Lithium bis
(perfluoroethylsulfonyl) imide (BETI) was obtained from Ionic Liquids Technologies
(Tuscaloosa, AL). Cell viability MTT (3-[4, 5-Dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium
bromide) and Mitochondrial ToxGloTM Assay kits were purchased from Promega Corporation
(Madison, WI). Triply deionized water (18.2 MΩ•cm) from an Elga model PURELAB ultra
water filtration system (Lowell, MA) was used for ion exchange reaction and nanoGUMBOS
preparations. A model 08849-00 cleaner (Cole-Parmer Instrument Company) was used for
preparation of nanoGUMBOS.
2.2.2. Synthesis and Characterization of IR780-based GUMBOS
The IR780-based GUMBOS were synthesized using an anion exchange method. First, 1
to 1.2 molar ratio of [IR780][I] and the counter-ion salts were dissolved in a mixture of
dichloromethane (DCM) and deionized water (2:1, v/v) and allowed to stir for 48 h at room
temperature. The organic phase was washed with fresh water several times to remove any
byproducts. The organic layer was removed in vacuo, followed by freeze-drying to remove
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traces of water. The obtained GUMBOS were confirmed by use of ESI-MS. Hydrophobicity of
each GUMBOS was determined by use of octanol-water partition. A standard calibration curve
of peak absorbance (y=790 nm) versus concentration of GUMBOS in 1-octanol was constructed
by using a UV/VIS spectrometer (PerkinElmer, Lambda 750). A known concentration of IR780based GUMBOS in 1-octanol was then mixed with equal volume of water and shaken for 24 h.
The upper 1-octanol layer was analyzed by use of UV/Vis near-IR spectrophotometer and
quantified using the standard calibration curve. The equation, K (o/w) = [GUMBOS] in octanol/
[GUMBOS] in water, was used to calculate the partition coefficient. It is worth noting that the 1octanol used in the partition experiments was pre-saturated with water overnight before use to
correct for mutual solubility of the two solvents.
2.2.3. Synthesis and Characterization of IR780-based NanoGUMBOS
NanoGUMBOS were prepared by use of a simple and additive-free reprecipitation
method. Typically, 20 µL of various concentration of GUMBOS dissolved in DMSO was rapidly
injected into 980 µL of cell media (DMEM containing 10% fetal bovine serum), followed by
sonication for 5 min in an ultrasonic bath (55 kHz). These nanoGUMBOS were aged in the dark
for 30 mins to complete growth. Formation of nanoGUMBOS can be easily controlled by
concentration of GUMBOS in DMSO, volume ratio of solvent (DMSO) and non-solvent (cell
media), as well as sonication time. For nanoGUMBOS characterization, the average particle size
and morphologies of prepared nanoGUMBOS were determined by use of transmission electron
microscopy (TEM). These TEM micrographs were recorded using an LVEM 5 transmission
electron microscope (Delong America, Montreal, Canada). A few microliters of nanoGUMBOS
suspension were drop-casted on a carbon-coated copper grid and allowed to air-dry at room
temperature. Upon drying, the grids were washed with fresh water several times to remove cell
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media and left to dry before TEM imaging. Hydrodynamic sizes of nanoGUMBOS at
physiological pH 7.4 were also measured via dynamic light scattering (DLS) by a Zetasizer Nano
ZS (Malvern Instruments, U.K.). NanoGUMBOS in cell media were centrifuged down at 35K
rpm, using a Beckman ultra-centrifuge, to obtain nanoparticle pellets, which were then resuspended in 0.01M phosphate buffered saline （ PBS ） for measurement. Zeta potential
measurements in 0.01M PBS with ionic strength 0.15M at various pH (pH=7.4 and pH=6.5)
were also performed by use of Zetasizer Nano ZS.
2.2.4. Spectroscopic Studies of GUMBOS and NanoGUMBOS
All absorbance measurements were conducted using a UV/VIS spectrometer
(PerkinElmer, Lambda 750). All fluorescence emission spectra were obtained using a Spex
Fluorolog-3 spectrofluorimeter (model FL3-22TAU3); Jobin Yvon, Edison, NJ). A 1 cm quartz
cuvette (Starna Cells) was used to collect the absorbance and fluorescence relative to an identical
cell filled with relevant solvent as the blank. Each GUMBOS was dissolved in acetonitrile to
make 2 µM solutions that were used for characterization of their spectral behavior including
absorption and fluorescence. Nanoparticles formed in serum-DMEM were diluted to 20 µM for
measurements. Serum-DMEM solution without nanoparticles was also measured as a control.
Colloidal stability of nanoparticles in serum-DMEM was monitored over 48 h by recording their
absorption spectrum at different time intervals.
2.2.5. Cell Culture
Hormone-independent human breast adenocarcinoma (MDA-MB-231, ATCC no. HTB26), hormone- dependent human breast adenocarcinoma (MCF7, ATCC no. HTB-22), normal
human breast fibroblast (Hs578Bst, ATCC no. HTB-125), normal human breast epithelial
(HMEC, ATCC no. PSC-600-010) and hormone-dependent pancreatic adenocarcinoma (MIA
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PaCa-2, ATCC no. CRL-1420) cell lines were obtained from the American Tissue Culture
Collection (ATCC, Manassas, VA). All cell lines were cultured in a humidified incubator at 37
o

C with 5% CO2 and grown to 90% confluence as per ATCC’s specifications before use in

further experiments.
2.2.6. Cell Viability Assay
Cytotoxicity of synthesized nanoparticles was assessed on different cell lines by use of
MTT assay (Promega Corporation, Madison, WI, USA). Briefly, 100 µL MDA-MB-23, MCF-7,
Mia Paca-2 and Hs578Bst were seeded in 96-well plates (~5000 cells/well) and allowed to grow
24 h for cell adhesion at 37 °C and 5% CO2 in a humidified incubator. Old culture medium was
removed, and 0.1 mL of new culture medium containing various concentrations of
nanoGUMBOS (0-12.5 µM) was introduced to the cells. After incubation with nanoGUMBOS
for 48 h, cells were washed twice with fresh cell media and 18 µL 3-(4,5-dimethylthiazol-2-yl)2,5-diphenylte-trazolium bromide (MTT) was added. After an additional 2 h of incubation, 100
µL of stop buffer solution (SDS/HCl) was added to each well and incubated overnight. Cell
viability was determined by measuring the absorption at 570 nm using a microplate reader
(PlateReader AF2200, Eppendorf). Cell viability was then calculated as the percentage of
absorbance from treated cells subtracted from the background absorbance, and absorbance of
untreated cells (control) subtracted from the background absorbance such that the control was
100% cell viability. IC50 value was calculated by use of non-linear regression with least square
fit in the GraphPad Prim 7 software.
2.2.7. Fluorescence Microscopy
Fluorescence images of live cells were recorded on a fluorescence microscope (Leica,
TCS SP5, Mannheim, Germany) equipped with a 40× water-dipping objective. Briefly, 200K
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cells in 2 ml of cell media were seeded on a 35 mm glass cover slip-bottomed petri dish (10 mm
micro cell; Ashaland, MA, USA) and allowed to grow for 24 h for cell adhesion at 37 °C and 5%
CO2 in a humidified incubator. To study co-localization of nanoGUMBOS with mitochondria,
10 nM of the MitoTracker Green (Beyotime Biotechnology Co., Ltd.) was used to stain
mitochondria for 30 min. Cells were then washed several times with fresh media, followed by
introduction of 1 µM nanoGUMBOS. After incubation for 30 min, cells were washed several
times with PBS and studied by fluorescence microscopy. A GFP filter tube (excitation: 450 nm
to 490 nm; emission: 500 nm to 550 nm) was used for MitoTracker Green, and a CY7 filter tube
(excitation: 672 nm to 748 nm: emission of 765 nm to 855 nm) was employed for IR780-based
nanoGUMBOS. Multicolor images were captured by high-speed frame sequential imaging.
Merged fluorescence images of MitoTracker Green dye with nanoGUMBOS were used for the
determination of sub-cellular localization of nanoGUMBOS. The same protocol has been used
for determination of cellular uptake of nanoparticles into cancer and normal cells.
2.2.8. Quantitative Cellular Uptake Measurement
Cellular uptake of different nanoGUMBOS into MDA-MB-231 cancer cells were
quantified by use of UV/VIS spectrometer (PerkinElmer, Lambda 750). In this case, 12.5 µM of
nanoGUMBOS in 2 mL cell media were added to a petri-dish with ~200,000 cells. After
incubation for 4 h, free particles in cell media were removed and cells were washed thoroughly
at least three times with PBS. The cells were digested by use of 3.5 mL DMSO, leading to the
exposure and dissolution of internalized nanoGUMBOS in this DMSO solution. The resulting
solution was analyzed by measuring absorbance from the GUMBOS against a DMSO-digested
untreated cell reference and quantitated using a standard calibration curve.
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2.2.9. Determination of Mitochondrial Responses
A Mitochondrial ToGloTM Assay kit, developed by Promega Corporation (Madison, WI),
was used to determine whether the drug is mitochondrial toxin. This assay was performed in
accordance with the manufacturer’s protocol.32 The experiment consists of two parts:1)
membrane integrity, and 2) ATP level after introduction of the test compound. Cell membrane
integrity (MI) was measured using a fluorogenic peptide substrate (bis-AAD-R110). This
substrate cannot across the membrane of live cells, and therefore, produces fluorescence that is
typically proportional to dead cells (cytotoxicity). Cellular ATP levels was measured by use of
the ATP detection reagent, which leads to viable cell lysis and generate a luminescent signal
proportional to the present ATP amount. Briefly, 10,000 cells/well of MDA-MB-231 were plated
using standard media in a white clear 96-well plate (Falcon®) and allowed to grow for 24 h for
cell adhesion. To restrict ATP production to oxidative phosphorylation, cells were washed in
serum-free, glucose-free, and galactose supplemented DMEM medium. All test compounds were
prepared in this medium. After washing, cells were incubated with test compounds containing
various concentrations (0-100 µM) for 2 h. Subsequently, 20 µL of a 5X diluted fluorogenic
peptide substrate (bis-AAF-R110) was added to each well and mixed by orbital shaking for 1
min at 600 rpm to ensure reagent/sample homogeneity. After 30 min of incubation at 37 °C,
fluorescence was measured at 530 nm using excitation at 485 nm by use of Wallac 1420 Victor2
microplate reader (Perkin Elmer) to assess membrane integrity (cytotoxicity). To determine the
amount of ATP, the sample plate was equilibrated to room temperature for 5-10 min. Then, 100
µL of ATP detection reagent were introduced to each well and mixed on an orbital shaker at 600
rpm for 5 min. Luminescence was measured for determination of ATP level. Data was expressed
as percentage of vehicle control containing no test compound.
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2.2.10. Bio-TEM Preparation
In order to study the intracellular stability of nanoparticles, bio-TEM was employed. In
brief, 1 µM of nanoparticles were incubated in 200,000 cells/dish for 30 min. The cells were
washed with PBS, scrapped from the culture plates, and collected into microcentrifuge tubes.
After that, fixative including 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M phosphate
buffer (pH=7.4) were added into each tube and wait for 10 min. The cell suspension was then
centrifuged, followed by removal of the supernatant. Same fresh fixative was added into the tube
on shaker for another 2 h and centrifuged again. The obtained cell pellets were mixed with equal
amount of 3% agarose, then transferred to a LM slide and was cut to cubes after it solidified. The
cell cubes were washed with phosphate buffer containing 0.08M glycine several times.
Following that, cells were fixed by 2% osmium tetroxide in phosphate buffer in dark for 2 h and
rinsed with deionized water. Then, cells were dehydrated through a graded ethanol series for 20
min each, and infiltrated with 1:1 EtOH and LR white and 100% LR White for 2 h, respectively.
Cell samples were then embedded in LR white and polymerized in an oven at 65 oC for 24 h.
Ultra-thin sections (90nm) for TEM were cut on a Leica EM UC7 Microtome, and then
transferred to a copper grid for Bio-TEM observation.
2.3. Results and Discussions
2.3.1. Synthesis and Characterization of IR780-based GUMBOS
All GUMBOS presented in this work were synthesized by use of a simple metathesis
reaction, where the anion of IR-780 was exchanged with a variety of bulky organic counteranions (structures provided in Figure 2.1). One scheme of a representative metathesis reaction
between [IR780][I] and lithium bis(perfluoroethylsulfonyl) ([Li][BETI]) is shown in Figure 2.2.
All GUMBOS obtained were then subjected to electrospray ionization mass spectrometry (ESI-
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MS) for confirmation of synthesis. The results from ESI-MS were consistent with theoretical
calculations (Table 2.1).
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Figure 2.1. Chemical structures of anions used: (a) ascorbate (Asc), (b)trifluoromethanesulfonate
(OTf), (c) bis(perfluoroethylsulfonyl) (BETI).
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Figure 2.2. Synthesis of [IR780][BETI] GUMBOS by use of anion exchange.
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LiI (aqeous phase)

Table 2.1. ESI-mass spectrometry analysis of all GUMBOS.
positive mode
GUMBOS

negative mode

Theoretical mass

Actual mass

Theoretical mass

Actual mass

(m/z)

(m/z)

(m/z)

(m/z)

[IR780][Asc]

540.2

539.3

175.2

175

[IR780][OTf]

540.2

539.2

149.1

149

[IR780][BEIT]

540.2

539.3

378.1

379.9

Table 2.2. Yields, melting points, logarithm of 1-octanol/water partition coefficients of
GUMBOS.
GUMBOS

[IR780][I]

[IR780][Asc]

[IR780][OTf]

[IR780][BETI]

Yields (%)

N/A

90

95

97

Melting point (°C)

232.5

246.3

212.6

150.8

0.93 ± 0.07

0.34 ± 0.09

0.74 ± 0.03

1.3± 0.1

Log(P)

As expected, the synthesized IR780-GUMBOS displayed variable physicochemical
properties with counter-anion variation, including properties such as melting point,
hydrophobicity, and optical behaviors (Table 2.2). Among these properties, hydrophobicity,
which affects the nanoparticle formation process and subsequent stabilization, of IR780-based
GUMBOS was estimated by use of octanol/water partition coefficients (logP) (Table 2.2).22
Comparison of anion variation indicates that [IR780][BETI] GUMBOS is the most hydrophobic,

52

followed by [IR780][I], [IR780][OTf], and [IR780][Asc]. Such differences in hydrophobicity is
quite dependent upon the counter-anion, which corroborates previous literature findings.2, 25 In
addition, optical behaviors of GUMBOS, including both absorption and fluorescence spectra
measured in acetonitrile, were evaluated and depicted in Figure 2.3(a) and (b), respectively. All
GUMBOS displayed similar absorption and emission spectra as the parent compound. The
absorption maximum was observed at 780 nm with a shoulder at 710 nm. The emission
maximum was measured to be 800 nm. Observed differences in absorbance and fluorescence
intensities of GUMBOS are likely a result of effects from anion variations. These IR780 based
GUMBOS also exhibited good NIR radiation absorption and strong fluorescence emission
similar to the parent dye. Such properties allow direct visualization of the distribution of
GUMBOS in cells or tissues through near infrared fluorescence (NIRF) imaging.33-34

Figure 2.3. (a) Absorbance spectra and (b) fluorescence emission spectra of IR780 and IR780based GUMBOS in acetonitrile.
2.3.2. Synthesis and Characterization of IR780-based NanoGUMBOS
Due to hydrophobic properties of IR780-based GUMBOS, nanoGUMBOS were prepared
by use of an additive free reprecipitation method in conjunction with ultra-sonication.25 Briefly, a
small aliquot of GUMBOS dissolved in dimethyl sulfoxide (DMSO) was rapidly injected into a
large amount of aqueous cell medium (Dul-becco Modified Eagel Medium (DMEM); containing
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10% fetal bovine serum) under ultrasonication. In this scenario, a high super saturation was
reached, thus initiating self-assembly of hydrophobic GUMBOS to form nanoparticles. The
resulting nanoparticle size was controlled by simple variation in initial concentration of
hydrophobic GUMBOS, which has also been used in fabrication of other size-controlled
hydrophobic nanodrugs.22, 35 As a result, the size of different nanoGUMBOS was optimized to
approximately 100 nm in this manner, which is considered excellent for tumor targeting and
accumulations owing to EPR effect. 36,37 Quasi-spherical or slightly ovate shapes were measured
for resulting nanoparticles by use of transmission electron microscopy (TEM). A histogram of
the TEM sizes are summarized in Figure 2.4(a-d), showing a narrow distribution of the actual
size of sample in a dried state. In addition, the hydrodynamic size of the nanoparticles was
evaluated in phosphate buffered saline (PBS) using dynamic light scattering (DLS). As shown in
Figure 2.5, all measured nanomaterials displayed a hydrodynamic size that is larger than 200 nm
due to aggregation in an aqueous solution system. Moreover, DLS analysis revealed that the
most hydrophobic GUMBOS, [IR780][BETI], yielded the most uniform nanoGUMBOS with a
polydispersity index of 0.12 (Figure 2.5). Such results also confirm the predominant role of
hydrophobicity on nanoparticle formation using a reprecipitation method as discussed
previously.22 Measurements of zeta potential suggest that all nanoGUMBOS displayed a
negative surface charge in PBS (Table 2.3). This indicates that the surfaces of the nanoparticles
are predominately anion controlled.
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Figure 2.4. Characterization of particle sizes for IR780-based nanoparticles using TEM.
Histograms constitutes 200 individual nanoparticles with a distribution curve overlay as well as a
representative portion of a TEM micrograph (all scale bars represent 500 nm): (a) [IR780][I], (b)
[IR780][Asc], (c) [IR780][OTf], (d) [IR780][BETI].
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Figure 2.5. Z-averaged diameter and PDI for IR780-based nanoparticles through DLS at 25 oC.
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Table 2.3. Zeta potential of IR780-based nanoparticles in 0.01M PBS buffer.
Nanoparticle

[IR780][I]

[IR780][Asc]

[IR780][OTf]

[IR780][BETI]

pH =7.4

-26 ± 2 mV

-25 ± 3 mV

-22 ± 5 mV

-24 ± 4 mV

pH = 6.5

-15 ± 5 mV

-26 ± 2 mV

-16 ± 4 mV

-21 ± 5 mV

Considering the application of IR780-based nanoGUMBOS in biological systems,
spectral behavior of these nanoparticles in serum-DMEM (10% FBS in DMEM, pH =7.4) was
also evaluated (Figure 2.6). Intriguingly, the relatively less hydrophobic [IR780][Asc] and
[IR780][OTf] nanoGUMBOS exhibited similar absorption spectra profile to the parent dye based
nanoparticles, where peak absorbance occurs at 790 nm with a shoulder at 720 nm. In contrast,
for the most hydrophobic compound, [IR780][BETI], the nanoparticle suspensions in serumDMEM displayed a slightly broader absorption spectra. This broadening from 820 nm to 900 nm
is consistent with formation of J-type aggregation as a result of staircase head-to-tail
arrangement of transition dipoles.38 All nanoparticles also displayed similar fluorescence spectra
with peak emission near 810 nm, which is in the desirable NIR region. This property allows for
NIRF imaging, making nanoGUMBOS more suitable for in vivo studies of bio-distribution due
to deep tissue penetration and low autofluorescence in comparison with many previously
reported fluorescent nanoparticles for chemotherapeutic applications.39-42 Of all nanoGUMBOS
studied, [IR780][Asc] and [IR780][BETI]

have shown more intense emission signal in

comparison to the parent dye. In addition, when compared to free IR780 in acetonitrile, a 10 nm
red-shift was observed for all investigated IR780-based nanoparticles in terms of both absorption
and emission spectra. This results from either a change in solvent polarity or from strong
hydrophobic interactions between IR780 and other molecules in the serum-DMEM, which is
consistent with previous literature data.15, 17
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Following initial photochemical examinations of these nanoGUMBOS, colloidal
stabilities of nanoparticles in cell culture medium were investigated since they play a profound
role in cellular uptake as well as cytotoxicity.43 A UV-Vis NIR spectrophotometer was used to
monitor absorbance spectra of all IR780-based nanoparticles in serum-DMEM over a 48 h period
as presented in Figure 2.7. It is interesting to note that an increase in peak absorbance at 790 nm
corresponding to randomly oriented aggregates was observed initially, with a decrease in
absorbance from 820 nm to 850 nm corresponding to J-aggregates. This indicates dyedeaggregation, where J-aggregation has shifted to randomly oriented aggregation. Similar results
have also been observed in previous studies of R6G nanoparticles.2 In the subsequent hours, little
or no change of spectra were observed (Figure 2.6c and Figure 2.7). This suggests formation of
stable nanoparticles under biological conditions, where nanoparticles are prevented from nonspecific adsorption on the walls of quartz cuvettes and stabilized in the presence of proteins in
serum-DMEM. Additionally, examination of size and shape of nanoGUMBOS after 48 h of
storage in cell culture media were also performed by use of TEM measurements. For example, as
shown in Figure 2.8, the sizes of all nanoGUMBOS were still approximately 100 nm with
spherical shapes after 48 h of storage in cell culture medium. Neither size, nor morphology of
nanoGUMBOS varied with time, which thus proved stability of these nanoparticles in cell
culture medium. This favorable stability of IR780-based nanoGUMBOS in cell culture medium
suggests potential use for future in vivo applications.
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Figure 2.6. (a) Absorbance spectra, (b) fluorescence emission spectra of IR780-based
nanoparticles, and (c) stability of IR780-based nanoparticles in serum-DMEM. Normalized
absorbance was determined by dividing the peak absorbance after certain hours by the initial
peak absorbance.
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Figure 2.7. Absorbance spectra corresponding to IR780-based nanoparticles in serum-DMEM as
a function of time showing transition from J-aggregation (λ = 820 nm) to randomly oriented
aggregation (λ = 790 nm) at the beginning of the experiment.

Figure 2.8. Characterization of particle sizes and morphology for IR780-based nanoparticles
after 48 h storage in cell culture medium using TEM, all scale bars represent 500 nm.
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2.3.3. In vitro Cytotoxicity Evaluation of IR780-based NanoGUMBOS
In vitro cytotoxicity of the parent [IR780][I] nanoparticles and the most uniform
[IR780][BETI] nanoGUMBOS were first evaluated using three different human cancer cell lines
including breast cancer (MDA-MB-231, MCF-7) and pancreatic cancer (MIA PaCa-2). These
cells were incubated using various concentrations of IR780-based nanoparticles for 48 h.
Subsequently, cell viability was examined and quantified using a colorimetric methyltetrazolium
(MTT) viability assay. The IC50 values of these cancer cells, which represent the concentration of
drug at 50% cell viability, were then calculated and compared. Figure 2.9(a) is a graph of IC50
values of parent [IR780][I] nanoparticles and [IR780][BETI] nanoGUMBOS for these different
cancer cell lines. The IC50 values of [IR780][BETI] nanoGUMBOS for the three cancer cell lines
were significantly smaller as compared with the parent dye, suggesting higher cytotoxicity of
nanoGUMBOS. Moreover, these results clearly reveal that among all the tested cancer cell lines,
the aggressive and invasive MDA-MB-231breast cancer cell line, was most susceptible to the
parent IR780 nanoparticles as well as [IR780][BETI] nanoGUMBOS.
The MDA-MB-231 breast cancer cells were used to further study differences in
therapeutic efficacy of all synthesized IR780-based nanoGUMBOS. As shown in Figure 2.9(b), a
significant reduction in IC50 concentration as compared to the parent dye was observed for all
investigated nanoGUMBOS. The [IR780][BETI] nanoGUMBOS were found to be most toxic to
cancer cells with the lowest IC50 value of 4.6 µM. This [IR780][BETI] nanoGUMBOS had more
than a threefold reduction in IC50 concentration as compared to the parent [IR780][I], with an
IC50 value of 17 µM. The other two nanoGUMBOS, [IR780][Asc] and [IR780][OTf] also
outperformed the parent dye in terms of anticancer efficacy, showing at least 1.5 fold lower IC50
concentrations. In comparison with R6G based nanoGUMBOS developed previously in our
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laboratory, IR780 based nanoGUBMBOS have shown enhanced toxicity towards cancer cells.2
Analysis of these results demonstrated the proven role of counter-ion variation on the toxicity of
such nanomaterials.
Examination of cytotoxicity on normal epithelial breast cells, i.e. Hs578Bst, was
performed to assess the selectivity of nanoGUMBOS. As presented in Figure 2.9(c-f), while all
nanoparticles exhibited a dose-dependent inhibition towards breast cancer cell proliferation, only
a small impact on the viability of normal breast Hs578Bst was observed under conditions tested.
For example, treatment of MDA-MB-231 cancer cells with [IR780][BETI] nanoGUMBOS led to
almost complete eradication of the cells at a concentration of 12.5 µM, while greater than 75%
cell viability of normal cells was still maintained. This suggests good selectivity of
[IR780][BETI] nanoGUMBOS towards cancer cells relative to normal cells. It is also interesting
to note that all IR780-based nanoGUMBOS displayed an enhanced selective toxicity towards
MDA-MB-231 cancer cell in comparison to the parent IR780 nanoparticles, as indicated by their
wider gap of cytotoxicity between cancer and normal cells. A similar selective outcome was also
observed for MCF-7 breast cancer cell line and HMEC normal epithelial breast cell line (Figure
2.10). In this case, the selective toxicity may be attributed to enhanced cellular uptake of
nanoGUMBOS in cancer cells relative to normal cells, as previously reported for the parent
IR780 in other cancer cell lines.13,

18, 44

This conclusion was further validated by use of

microscopy studies in which higher fluorescence intensity was observed in cancer cells relative
to normal cells after treatment with the same concentration of nanoGUMBOS (Figure 2.11).
Examination of these results suggest that anion exchange with parent compound aided in
improvement of anti-tumor effects while still displaying good selectivity in vitro. Thus, our
nanoGUMBOS may be good candidates for further exploration as potential therapeutic drugs.
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Figure 2.9. (a) The IC50 values of [IR780][I] nanoparticles and [IR780][BETI] nanoGUMBOS
for cultured MDA-MB-231, MCF-7, and MIA PaCa-2 cancer cells.(b) The IC50 values of
different IR780-based nanoparticles for MDA-MB-231. (c-f) Cell viability for MDA-MB-231
cancer cell and Hs578Bst normal cell after treatment of IR780-based nanoparticles for 48 h. Data
are presented as mean ± s.d.(n=6). Statistical significance was assessed by use of SPSS via oneway ANOVA test;( **P ≤ 0.05, ***P ≤ 0.001, ****P ≤0.0001).

Figure 2.10. Cell viability of HMEC and MCF-7 cell lines upon treatment after being incubated
with IR780-based nanoparticles for 48 h.
62

[IR780][BETI]

[IR780][Asc]

[IR780][OTf]

Hs578Bst

MDA-MB-231

[IR780][I]

Figure 2.11. Cellular uptake of IR780-based nanoparticles in MDA-MB-231 cancer cells and
Hs578Bst normal cells. Fluorescence microscope was used to detect accumulation of
nanoparticles.
2.3.4. Cellular Uptake Studies
Effective cellular uptake plays an important role in enhancing nanoparticle retention,
EPR effects, and ultimately therapeutic efficacy.45 In order to further understand improved drug
efficacy of nanoGUMBOS as compared to the parent dye, the cellular uptake of all nanoparticles
with different absorptivity were quantitatively measured and compared using a previously
reported method with slight modification.26, 46-47 An optimized concentration of nanoparticles
corresponding to little or no cell death was incubated with MDA-MB-231 cancer cells for 4h,
and then cellular uptake of incubated nanoparticles were quantified based on spectrometric
measurements. As shown in Figure 2.12, all nanoGUMBOS exhibited significantly higher
cellular uptake than the original [IR780][I] nanoparticle, which suggests a greater amount of
nanoGUMBOS accumulated inside the breast cancer cells. These results further corroborate the
observed enhanced cancer killing activity of nanoGUMBOS. Since uptake of nanoparticles
commonly occurs through receptor-mediated pathways, this process is largely influenced by the
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physicochemical properties of nanoparticles including hydrophobicity, size, surface charge, and
composition.48-49 Therefore, shape and size of all nanoparticles were characterized to ensure that
all exhibited similar properties. Internalization of [IR780][I] has previously been demonstrated to
depend upon organic anion transporting polypeptides (OATPs), more specifically the OATP1B3
subtype.12-13,

18

Therefore, we hypothesize that counter-ion exchange probably promotes

interaction with OATPS transporters, leading to higher uptake.
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Figure 2.12. Cellular uptake of nanoparticles after incubation of 25nmol NPs with MDA-MB231 cancer cells. Data are presented as mean ± s.d.(n=3). Statistical significance was assessed by
SPSS via one-way ANOVA test;( **P ≤ 0.05, ***P ≤ 0.001, ****P ≤0.0001).
2.3.5. Intracellular Stability Studies
Due to complexity of the intracellular environment, in which various enzymes and
hydrolases coexist, internalized nanoparticles generally undergo degradation and have a
decreased chance of reaching the target organelle in order to exert its function.50 Thus, following
evaluation of cellular uptake, I then investigated the effect of the intracellular stability of all
nanoGUMBOS on drug efficacy. By use of bio-TEM, change of nanoparticles behaviors after
internalization into cancer cells was tracked. As indicated in Figure 2.13(a), only a few [IR780][I]
nanoparticles were observed inside MDA-MB-231 cancer cells after 30 min incubation. This
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phenomenon most likely resulted from dissociation or degradation of the internalized
nanoparticles that has been confirmed previously through detection of strong fluorescence from
the parent dye based nanoparticle (Figure 2.11). In contrast, a large number of IR780 based
nanoGUMBOS were present in the cytoplasm and still maintained intact morphology as shown
in Figure 2.13(c-d). In this regard, rather than undergoing degradation, most nanoGUMBOS
proceeded to aggregate into large particles or clusters after internalization into cells. Thus, it is
reasonable to expect that the aggregation behavior of nanoGUMBOS helps their retention in
cancer cells long enough to reach the target organelle. This is also consistent with enhanced
accumulation of nanoGUMBOS as shown in our cellular uptake study.
(a)

(c)

(b)

(d)

Figure 2.13. Bio-TEM images of MDA-MB 231 cells incubated with (a) [IR780][I] nanoparticles,
(b) [IR780][OTf], (c) [IR780][Asc], and (d) [IR780][BETI] nanoGUMBOS for 30 min. Insets
are the enlarged images corresponding to the red rectangle sections of each image, showing the
presence of nanoparticle.
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2.3.6. Mechanism of Anticancer Effect of IR780-based Nanoparticles
Since all IR780 based nanoGUMBOS have shown efficient cellular uptake, good
intracellular stability, and good cancer killing activity, the mechanism of cancer toxicity also
needs to be determined for future applications. It is well established that IR780 dye preferentially
accumulates in the mitochondria of cancer cells in order to induce cell apoptosis.13, 44 In this
context, I also examined sub-cellular localization of our nanoGUMBOS (represented as red
fluorescence) by co-staining with MitoTracker green dye (represented as green fluorescence) in
breast MDA-MB 231 cancer cells. As presented in Figure 2.14(a), strong fluorescence from
IR780-based nanoGUMBOS was observed indicating the effective internalization of
nanoGUMBOS. The merged images show a large yellow overlay of red fluorescence from
nanoGUMBOS and green fluorescence from the MitoTracker dye. This suggests that similar to
the [IR780][I], all nanoGUMBOS also primarily accumulate in the mitochondria in breast cancer
cells, indicating that the mitochondria may also be a major target organelle of IR780-based
nanoGUMBOS in order to induce cell death. Additionally, the Pearson’s coefficients measuring
degree of co-localization of nanoGUMBOS and MitoTracker were calculated to be larger than
0.7 (Table 2.4), quantitatively confirming the great mitochondria localization of nanoGUMBOS.
To elucidate the specific mechanism of cancer toxicity for these nanoGUMBOS, a mitochondrial
toxicity assay in combination with the galactose cell culture growth medium was further
performed, which allows prediction of potential mitochondrial dysfunction as a result of drug
exposure.32 This assay consists of two measurements, including cell membrane integrity (MI)
associated with cytotoxicity, and cellular ATP levels. Typically, a mitochondria toxin inhibits
oxidative phosphorylation, resulting in decreased ATP with no change or disproportional
increase in its measured cytotoxicity as compared to the vehicle control. In contrast, a reduction
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in ATP with a proportional increase in cytotoxicity suggests primary necrosis is occurring
instead of mitochondria dysfunction.2 As shown in Figure 2.14(b), cells treated with these
nanoGUMBOS displayed similar results as the parent dye, in which ATP levels were reduced
with a disproportional increase in cytotoxicity relative to the vehicle control, indicating all
IR780-based nanoGUMBOS are also mitochondrial toxins. Similar mitochondria toxicity
profiles of other known mitochondrial toxins such as antimycin and rhodamine 6G were also
observed in other literature.2,

30

Therefore, it can be concluded that cancer toxicity of these

nanoGUMBOS, as well as the parent dye arise from inhibition of oxidative phosphorylation in
the mitochondria of MDA-MB-231 cancer cells. In comparison to other nanoparticles that act
through a similar mitochondria-based anticancer route, most of the reported literature has
involved use of various materials to achieve targeting function.41-42 In contrast, our IR780 based
nanoGUMBOS target the cancer cell mitochondria due to the cationic charge of IR780, and
displayed selective toxicity towards cancer cells without use of any other targeting moiety.
Table 2.4. Pearson’s coefficients for co-localization of nanoGUMBOS and MitoTracker green
calculated using Fiji Coloc2.
Compound

Pearson’s coefficient

[IR780][I]

0.91

[IR780][OTf]

0.88

[IR780][Asc]

0.77

[IR780][BETI]

0.92
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Figure 2.14. (a) Co-localization of IR780-based nanoGUMBOS with MitoTracker dye imaged
by use of fluorescence microscope. All scale bars on the fluorescence microscopy images
represent 20 µm. (b) Profiles of mitochondria toxicity of IR780-based nanoGUMBOS using a
mitochondrial ToxGlo TM assay.
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2.4. Conclusion
In this study, I outline a simple counter-ion variation strategy to design a series of tunable
nanoGUMBOS based on IR780, a known NIR anticancer dye. These novel IR780-based
nanoGUMBOS are easily synthesized with a size of approximately 100 nm. Moreover, our
nanoGUMBOS possess high stability in true biological systems as observed in the bio-TEM
study. Most importantly, all nanoGUMBOS displayed enhanced selective cytotoxicity towards
breast cancer cells in the absence of targeting molecules when compared with the parent dye.
Comparison of cytotoxicity results of all nanoGUMBOS suggests that [IR780][BETI] displays
the best drug efficacy towards MDA-MB-231 breast cancer cells with minimum toxicity towards
normal breast cells, followed by [IR780][Asc], and then [IR780][OTf]. Mitochondrial assays
revealed that anticancer effects of the nanoGUMBOS results from mitochondria dysfunction. In
conclusion, our findings provide enhanced insight and encourage further investigations of IR780based nanoGUMBOS as chemotherapeutic agents, as well as use in combination with PDT or
PTT for improved cancer therapy.
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CHAPTER 3. A TUMOR TARGETING NIRF NANOGUMBOS WITH
CYCLODEXTRIN ENHANCED CHEMO/PHOTOTHERMAL ANTITUMOR
ACTIVITIES
3.1. Introduction
Recent developments in cancer therapy have resulted in a tremendous increase in
investigations using theranostic agents, i.e., materials integrating both therapeutic and diagnostic
imaging modalities. Such theranostics allow delivery of therapeutic drugs and diagnostic imaging
agents simultaneously via a single dose. This overall strategy results in accelerated drug
development, reduced side effects, and reduced cost relative to use of separate materials for
theranostic applications.1-3
Near infrared fluorescent (NIRF) dyes have emerged as promising theranostic agents since
such drugs concomitantly serve as imaging agents and as agents for photothermal therapy (PTT)
and photodynamic therapy (PDT). Several advantages accrue from the use of NIRF dyes for
biomedical applications including low auto-fluorescence, deep tissue penetration, and minor
invasiveness for phototherapy. Thus, the combined advantages of such dyes result in high
sensitivity for imaging and high therapeutic efficacy.4-6 IR780 is a NIRF heptamethine dye with
peak absorption at 780 nm and is recognized as an excellent theranostic agent. It has been widely
studied for applications in imaging, PTT, and PDT due to its strong fluorescence intensity and
superior tumor targeting properties.7-11 As a lipophilic cationic dye, IR780 has also been shown to
preferentially accumulate in the mitochondria of cancer cells, resulting in cell death.11 Since the
mitochondria is known to be highly sensitive to hyperthermia and excessive reactive oxygen
species (ROS),12-13 these mitochondrial properties have been exploited to design drugs with
enhanced PTT and PDT effects.14-17 In this regard, the mitochondrial targeting property of IR780
also makes it a favorable drug for PTT and PDT applications. Despite these attractive properties,
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these auxiliary application of IR780 for cancer treatment is still hindered by poor aqueous stability,
photobleaching, severe toxicity at high doses, and rapid elimination from the body.18 In order to
address these issues, considerable effort has been expended to encapsulate IR780 into various
nanoscale delivery vehicles including micelles, proteins, or polymeric nanoparticles.5, 7, 19 In this
context, the hydrophobic IR780 can be delivered to tumor tissues and retained for extended periods
by use of passive targeting mechanisms such as enhanced permeation and retention (EPR) effects
due to the hyper vasculature of tumor tissues.20 However, delivery of IR780 using these
nanocarriers remains a challenge due to the complexity of fabrication, limited drug-loading
capacity, and diminished chemotherapeutic activity.2, 7, 9, 19, 21
Our research has focused on developing a new class of nanomaterials called
nanoGUMBOS, derived from a group of uniform materials based on organic salts (GUMBOS),
for various biomedical applications.22-24 GUMBOS are solid phase organic salts with highly
tunable physicochemical properties achieved via counter-ion variation. NanoGUMBOS are
nanomaterials derived from GUMBOS and combine the versatility of GUMBOS while displaying
enhanced properties at the nanoscale level. More importantly, using nanoGUMBOS as nanodrugs
allows ultra-high drug loading and selective cytotoxicity as observed in one of our previous
studies.22 The size and aqueous stability of nanoGUMBOS can also be easily tailored for further
optimization of drug efficacy through EPR effects. Several investigations have been performed in
our laboratory for controlled synthesis of nanoGUMBOS. In these studies, templated synthesis of
nanoGUMBOS using cyclodextrin (CD) has been shown to produce uniform and stable
nanoparticles.25 Moreover, CDs possess a unique cone structure with a hydrophilic exterior and a
relatively hydrophobic cavity, that may allow encapsulation of hydrophobic drugs within the
cavity for enhanced water solubility and protection of the active drugs from light-, thermal- and
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oxidative-degradation.26
In the study reported here, I have designed and synthesized an IR780-based GUMBOS as
a prodrug, followed by conversion to nanoGUMBOS for enhanced in vitro and in vivo
chemo/photothermal antitumor effects. Optimization of nanoGUMBOS fabrication with regard to
size and aqueous stability is achieved by use of a reprecipitation method in the presence of various
forms of β-CD. The cavity size of β-CD is preferred over other CDs for encapsulation of typical
drug molecules.27-28 Following fabrication of CD-based nanoGUMBOS, characterizations
regarding size, morphology, stability, and photophysical properties were performed. Subsequently,
in vitro cytotoxicity (with and without NIR irradiation), cellular uptake, and subcellular
localization were evaluated using human breast cancer cell lines. Tumor targeting studies were
also performed using in vivo NIRF imaging. Finally, the antitumor efficacy of chemo/photothermal
treatment was evaluated using a MDA-MB-231 tumor xenograft mouse model to explore the
potential use of CD-based nanoGUMBOS as theranostic cancer therapeutic agents.
3.2. Materials and Methods
3.2.1. Materials
IR780 iodide (98%), sodium tetraphenyl borate (99.5%)(TPB), methylene chloride (DCM),
chloroform, methanol, anhydrous acetonitrile, and phosphate buffered saline (1´PBS) were
purchased from Sigma-Aldrich (St. Louis, MO). b-cyclodextrin (b-CD) and (2-hydroxypropyl)-bcyclodextrin (HP-b-CD) were purchased from Fluka (Germany). The cell viability agent (3-[4, 5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was purchased from Promega
Corporation (Madison, WI). MitoTracker Green was purchased from ThermoFisher Scientific
(Waltham, MA). Triply deionized water (18.2 MΩ•cm) obtained from an Elga model PURELAB
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ultra water filtration system (Lowell, MA) was used for the ion exchange reaction and
nanoGUMBOS preparations.
3.2.2. Preparation of [IR780][TPB] GUMBOS and NanoGUMBOS
IR780 GUMBOS were synthesized by use of two-phase anion exchange method similar to
that described in previous literature.10 In this case, IR780 (30 mg) was dissolved in 10 mL of DCM,
and 5 mL of sodium tetraphenyl borate (10 mg) in water was added. This mixture was stirred for
48 h at room temperature. Subsequently, the water layer was decanted, and the organic phase was
washed with fresh deionized water several times to remove any sodium iodide and extra sodium
tetraphenyl borate byproducts. The final products were obtained by removal of organic solvent in
vacuum and traces of water under freeze-drying, providing an overall product yield of
approximately 97%. NanoGUMBOS were prepared in water using a reprecipitation method.
Briefly, a small aliquot (200 µL) of 10mM GUMBOS solution in acetone was added to a vial
containing 10 mL of deionized water, followed by 5 min of sonication. NanoGUMBOS suspension
was then kept in the dark for 30 min to complete growth. Following that, nanoGUMBOS were
harvested with centrifugation at 35000 rpm for 30 min, and the supernatant was discarded. The
nanoGUMBOS pellet obtained was finally washed with fresh water several times and lyophilized
using a vacuum freeze dryer at -50° C.
3.2.3. Preparation of CD-based NanoGUMBOS
In order to improve bioavailability of nanoGUMBOS, CD-based nanoGUMBOS were
prepared by use of a freeze-drying method in conjunction with ultrasonication. Briefly, 200 µL of
10 mM GUMBOS in acetone was dropwise added into 10 mL of water solution containing
different amount of CD. This mixture was sonicated using a bath sonication for 5 min. This
solution was then stirred for 1 h for evaporation of acetone, and observed precipitates were filtered
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out. Finally, the remaining filtrate was freeze-dried at -50 °C for 48 h. Using this approach,
different types of CD including b-CD and HP-b-CD with 0.6 degree of substitution were
investigated using two molar ratios of [IR780][TPB] to CD (1:1 and 1:2).
3.2.4. Differential Scanning Calorimetry
Thermal analyses of HP-b-CD, GUMBOS, physical mixture of GUMBOS and HP-b-CD,
and CD-based nanoGUMBOS were performed using a DSC 4000 system (PerkinElmer Inc, USA).
Briefly, one to five milligrams of samples were heated in sealed aluminum pans at the speed of
5 °C /min in a dynamic nitrogen atmosphere with a flow rate of 20 mL/min. An empty aluminum
pan was used as the reference. Thermogram of each sample was recorded.
3.2.5. Photothermal Measurements
Temperature profiles of nanoGUMBOS and CD-based nanoGUMBOS were evaluated
using a tip thermometer. In brief, 1 mL of each nanoGUMBOS with 100 µM IR780 equivalent in
water was prepared in a UV-vis cuvette. The solution was then irradiated using an 808 nm laser
(Lasermate Group, Inc., Walnut, CA) at a power density of 0.5 W/cm2 for 10 min. Temperatures
were recorded every 30 s. An equivalent amount of water under the same laser irradiation was set
as the negative control.
3.2.6. Cell Culture
The estrogen-independent human breast adenocarcinoma (MDA-MB-231, ATCC No.
HTB-26), human breast carcinoma (Hs578T, ATCC HTB-126), estrogen-dependent human breast
adenocarcinoma (MCF-7, ATCC No. HTB-22), normal human breast fibroblast (Hs578Bst, ATCC
No. HTB-125), and human mammary epithelia cells (HMEC, ATCC PCS-600-010) were obtained
from the American Tissue Culture Collection (ATCC, Manassas, VA). The MDA-MB-231 cell
line was maintained in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich),
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supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich). The Hs578T and MCF-7 cell
lines were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL
penicillin and 100 µg/mL streptomycin (Sigma-Aldrich). The Hs578Bst cell line was maintained
in ATCC Hybri-Care Medium, 30 ng/ml mouse EGF and 10% FBS. Mammary Epithelial Cell
Basal Medium (ATCC) was used for the cultivation of HMEC cell line supplemented with a
Mammary Epithelial Cell Growth Kit (ATCC) containing 5 µg/ml hH-insulin, 6 mM L-glutamine,
0.5 µM epinephrine, 5 µg/mL apo-transferrin, 5 ng/mL rH-TGF-α, 0.4% ExtractP and 100 ng/mL
hydrocortisone hemisuccinate. All cell lines were cultured in a humidified incubator at 37° C with
5% CO2 and grown to confluence as described by ATCC protocol specifications before use in
further experiments.
3.2.7. Cell Viability Assay
In vitro cell toxicity was determined by use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, MDA-MB-231, Hs578T, MCF-7, Hs578Bst, and HMEC
were cultured in 96-well plates with 5000 cells per well and treated with nanoGUMBOS in various
concentration from 0 to 50 µg/mL for 48 h. After that, cells were washed twice with fresh cell
medium, and 18 µL MTT was added in each well. Following an additional 2 h of incubation, 100
µL of stop buffer solution (10% SDS/0.01M HCl) was added to each well for solubilization of the
formazan crystals produced. After overnight incubation, absorbance was measured at 570 nm
using a microplate spectrophotometer (Eppendorf, Hauppauge, NY). Percent cell viability was
then determined using the untreated cells as 100% viability.
For in vitro PTT efficiency, MDA-MB-231 and Hs578T cancer cells were cultured in black
96-well plates with 10,000 cells per well and incubated with different concentrations of
nanoGUMBOS (3.125 µg/mL, 0.78 µg/mL, 0.39 µg/mL). Following 24 h of incubation, non-
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internalized nanoparticles were washed away using fresh cell medium, and cells were irradiated
by an 808-nm laser at 0.5 W/cm2 for 5 min with another 24 h of incubation. Subsequently, the cell
viability was determined by MTT assay. Untreated cells were used as controls.
3.2.8. Cellular Uptake and Subcellular Localization
Cellular uptake of nanoGUMBOS was measured using MDA-MB-231 cancer cells. Cells
were seeded in 6 well-plate with 200,000 cells per well in 2 mL of cell medium and cultured for
48 h. The medium was replaced with a fresh medium containing 12.5 µg/mL of nanoparticles.
After incubation for different time (0.5, 1, 2, 3, and 4 h), cells were washed with PBS thoroughly
and digested by use of DMSO for exposure and dissolution of internalized nanoGUMBOS before
analysis using a Spex Fluorolog-3 spectrofluorimeter (Horiba Scientific, Edison, NJ).
For study of subcellular localization, MDA-MB-231 cancer cells with 200,000 were
cultured on 35 mm glass-bottomed cell culture dishes (MatTek Corporation, Ashland, MA) for 48
h to achieve cell confluency. First, 20 nM of the MitoTracker Green (Beyotime Biotechnology Co.,
Ltd.) was used to stain mitochondria for 30 min. After that, 12.5 µg/ml of nanoGUMBOS were
incubated for 1h. The cells were then washed several times with PBS thoroughly. All images were
captured using a Leica TCS SP5 fluorescence microscope (Mannheim, Germany) equipped with a
40× water dipping objective. Merged fluorescence images of tracker dye with nanoGUMBOS were
used for the determination of sub-cellular localization of nanoGUMBOS.
3.2.9. MDA-MB-231 Xenograft Mouse Model
An MDA-MB-231 derived cell line that stably expressed luciferase (referred to as MDAMB-231-luc) was a generous gift from Dr. Suresh Alahari, Louisiana State University School of
Medicine, New Orleans, LA. Female 3 to 6 week old athymic nude mice (Envigo RMS, Inc.;
Indianapolis, IN) were used for all the in vivo studies. All animal experiments were carried out in
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compliance with IACUC guidelines of Louisiana State University, and humane care of animals
was ensured. A breast tumor xenograft model was established by subcutaneous injection of 0.2
mL MDA-MB-231-luc cells (5´ 106 cells/mL in PBS) into the right flanks of the mice. The tumor
volumes were monitored by in vivo luciferase imaging weekly after injection of the cells. Ten
minutes before the luciferase imaging procedure, the mice were injected intraperitoneally with Dluciferin (150 mg/kg in PBS). The mice were then anesthetized with 3% isoflurane, and
luminescent images were acquired using a Spectral Ami imaging system (Spectral Instruments,
Tucson, AZ). Tumor volumes were also determined via daily measurements of the smallest (d)
and the largest (D) diameters with calipers, and volumes were calculated employing the formula:
V = D × d2 × 0.52.
3.2.10. In vivo and Ex vivo NIRF Imaging
In this experiment, 6 mice were injected with 0.2 mL MDA-MB-231-luc cells (5´ 106
cells/mL in PBS) into the right flank. When the tumors grew to approximately 200 mm3, the tumorbearing mice were randomly divided into 3 groups with 2 mice in each group and intravenously
injected via the tail vein with PBS, [IR780][TPB] nanoGUMBOS (1.5 mg/kg), or CD[IR780][TPB] nanoGUMBOS (1.5 mg/kg [IR780][TPB] equivalent). Subsequently, in vivo
biodistribution in each mouse was evaluated by using a Spectral Ami imaging system (Spectral
Instruments, Tucson, AZ). Images were acquired from anesthetized mice at 3, 6, 24, 48, 72, 96,
and 120 h after injection. All the mice were euthanized at 120 h post-injection, and the tumor tissue
and major organs including the heart, liver, spleen, lung, and kidneys were collected and analyzed
by fluorescence imaging. The acquisition parameters used an excitation at 745 nm and emission
at 810 nm.
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3.2.11. In vivo Temperature Measurements and Chemo/Photothermal Therapeutic Effects
In this experiment, 24 mice were injected with 0.2 mL MDA-MB-231-luc cells (5´ 106
cells/mL in PBS) into the right flank. When the tumors grew to approximately 50 mm3, tumorbearing mice were randomly divided into four treatment groups (n = 6). The following treatments
included PBS (200 µL), PBS (200 µL) plus laser therapy, CD-[IR780][TPB] nanoGUMBOS (3
mg/kg), and CD-[IR780][TPB] nanoGUMBOS (3 mg/kg) plus laser therapy, respectively. All
treatments were intravenously injected via the tail vein. At 72 h post-injection, mice anesthetized,
and laser irradiation was applied on the tumor area for 2 min using an 808 nm laser (Lasermate
Group, Inc., Walnut, CA) at a power density of 2.0 W/cm2. A NIR detection card was used to align
the laser beam with the tumor area. To determine the temperature of tumor, photothermal images
were captured every 10 sec using an FLIR thermal imaging camera (FLIR, Wilsonville, OR).
Meanwhile, tumor sizes of each group were recorded with a vernier caliper every other day to
evaluate the therapeutic effects. The injection day was designated as day 0, and tumor volume was
calculated using the formula: V = D ´ d2 ´ 0.52, where D and d the largest and smallest diameter
of tumor, respectively.
3.2.12. Statistical Analysis
All experiments were performed in triplicate at least three times. Data are presented as the
mean ± standard deviation of the data points. For cell viability studies, in vivo biodistribution
studies, and in vivo tumor growth study, a two-way ANOVA analysis was used with Bonferroni
post-test. Statistical calculations were performed using GraphPad Prism 7.0 software (GraphPad
Software; La Jolla, CA, USA). Data were considered statistically significant when p<0.05.
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3.2.13. Computational Methods
Electronic structure calculations. The initial coordinates of HP-𝛽-CD, IR780 and TPB
were generated with OpenBabel29 with corresponding SMILES string. All initial structures were
optimized at the level theory of B3LYP/6-31G* and restrained electrostatic potential (RESP)
charges were calculated by using HF/6-31G* as the level of theory.30 Gaussian 09 software
package was used to performed geometry optimizations and charge calculations.31
Docking simulations. GOLD software (version 5.6.3) was used to perform dockings.32
IR780 and TPB were used as two separate ligands, while HP-𝛽-CD was used as receptor. Center
of mass of HP-𝛽-CD was set to the reasonable binding site since ligands could be inserted deeply
into the HP-𝛽-CD molecules due to their large cavity in the center. The docking solution with the
highest fitness score was treated as the stable binding complex.
Molecular dynamics (MD) simulations. MD simulations were performed by use of
Amber 16 software package.33 The general amber force field (GAFF) was used to model binding
complexes.34 LEAP, and Antechamber modules in Amber 16 were used to generate topologies and
parameters. The force field parameters related to boron used in this study are shown in Table 3.1.
The stable binding complexes from docking simulations were used as the initial structures
of MD simulation. Each binding complex was solvated in TIP3P water35 shell with 15 Å thickness.
In addition, Na+ or Cl- counter-ions were added to neutralize the system. Each solvated system was
minimized with steepest descent algorithm for 1000 steps and followed by a conjugate gradient
minimization of 1000 steps. The coordinates of the binding complex were kept fixed during the
minimization process.
Each solvated system was slowly heated from 0 to 300K for 10 ns in Canonical (NVT)
ensemble, followed by 90 ns equilibrium and another 10 ns production at 300K with an average
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pressure of 1 atm in Isothermal–isobaric (NPT) ensemble. During the MD simulation, a time step
of 1 fs for integration, 8 Å cut-off for nonbonded interactions, and particle mesh Ewald36 for longrange interactions were employed as common simulation protocols. SHAKE algorithm was used
to constrained bonds involving hydrogen.37 The temperature was controlled by Langevin
dynamics38 using a collision frequency of 2.0 ps-1 and pressure was maintained by Isotropic
position scaling39 with a relaxation time of 2 ps. The 10 ns production runs were used to calculate
the binding free energy with MM/GBSA method using MMPBSA.py.40-41
Table 3.1. Force field parameters related to boron.
Van der Waals parameters
Well depth(kcal/mol)

Radius(Å)
B

2.15042

0.14042

Bond Parameters

B-C

Reference distance (Å)

Force constant (kcal/mol2/Å2)

1.53943

671.7143

Angle Parameters
Reference Angle(degree)

Force constant (kcal/mol2/rad2)

B-C-C

124.543

54.65743

C-B-C

110.0

82.130

Dihedral Parameters

C-B-C-C

Barrier height(kcal/mol)

periodicity

Phase(degree)

0.5

2

180
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3.3. Results and Discussions
3.3.1. Synthesis and Characterization of GUMBOS
The IR780-based GUMBOS reported in this study were synthesized by pairing cationic
IR780 with the lipophilic tetraphenylborate (TPB) using a metathesis reaction as shown in Figure
3.1(a). This counter-anion is chosen to facilitate the transfer of IR780 cation into mitochondria for
enhanced PTT effects, as previously demonstrated in other literature.44 Formation of the IR780
GUMBOS was confirmed using electrospray ionization mass spectrometry (ESI-MS) (Figure 3.2).
A high percentage yield of 97% was achieved. The [IR780][TPB] GUMBOS synthesized
displayed a larger octanol/water partition coefficient (log P = 0.18) as compared to the parent
compound [IR780][I] (log P = 0.09), indicating enhanced hydrophobicity upon anion exchange
with TPB. This enhanced hydrophobicity should be a favorable characteristic for interacting with
cell membranes, leading to higher cellular uptake as well as mitochondrial accumulation.45
Additionally, such tunable hydrophobicity of GUMBOS may aid in formation of nanoGUMBOS
in an aqueous system.46 The absorption and fluorescence behaviors of GUMBOS were also
evaluated in acetonitrile. As shown in Figure 3.3, these GUMBOS displayed similar absorption
and emission spectra as the parent compound due to the IR780 cationic backbone. The absorption
maximum was observed at 780 nm with a shoulder at 710 nm, while the emission maximum was
at 800 nm.
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Figure 3.1. (a) Depiction of a metathesis reaction for the synthesis of [IR780][TPB] GUMBOS.
(b) schematic representation of the formation of CD-based nanoGUMBOS using HP-β-CD and
[IR780][TPB] GUMBOS.

Figure 3.2. ESI-mass spectra of [IR780][TPB] GUMBOS at positive mode and negative mode.
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Figure 3.3. Absorption spectra and fluorescence spectra of 2 µM of [IR780][I] and [IR780][TPB]
in acetonitrile.
3.3.2. Preparation and Characterization of NanoGUMBOS
To examine application of [IR780][TPB] GUMBOS in a biological system, sizecontrollable nanoGUMBOS and CD-based nanoGUMBOS were prepared by use of a facile and
green method with and without CD, respectively. Owing to the hydrophobic properties of
[IR780][TPB] GUMBOS, they can be directly converted into nanoGUMBOS through selfassembly in an aqueous medium.10,

47

In this regard, the control nanoGUMBOS were firstly

prepared using a reprecipitation method without CD.10 The formation of such nanoGUMBOS was
confirmed using transmission electron microscopy (TEM) and dynamic light scattering (DLS). As
indicated by TEM measurements, spherical nanoGUMBOS were obtained with approximately
average size of 88 ± 17 nm under dried conditions (Figures 3.4a and 3.4b). In contrast, the
hydrodynamic size of these nanoparticles was 169 ± 2 nm with a polydispersity index (PDI) of
0.12 in DLS. Variation in size analyses using TEM and DLS could be attributed to aggregation in
the solution system, resulting in larger size than in the dried state. The zeta potential of
nanoGUMBOS at pH 7.4 was measured to be -27 mV, indicative of an overall negative surface
charge under physiological condition. However, the hydrodynamic size of the control
nanoGUMBOS in PBS determined by DLS increased significantly from 169 nm to 320 nm after
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24 h. A large PDI of 0.5 was also obtained, indicating aggregation of nanoGUMBOS in PBS as a
result of hydrophobicity of GUMBOS.
To further improve stability of nanoGUMBOS in an aqueous system, CD-based
nanoGUMBOS were fabricated by use of ultrasonication in conjunction with freeze-drying. A
schematic representation of the formation of such nanoparticles is shown in Figure 3.1b. In this
scenario, CD serves as a drug carrier to partially or completely incorporate lipophilic GUMBOS
in the hydrophobic cavity, followed by self-assembly into nanoparticles using ultrasonication. In
order to optimize fabrication of these nanoparticles for chemo/photothermal therapeutic
applications, different molar ratios of GUMBOS and CD including β-CD and HP-β-CD were used.
The loading capacity of resulting nanoparticles was characterized. As shown in Table 3.2,
increasing the ratio of CD resulted in a slight reduction in loading capacity of nanoparticles, which
is also in agreement with observations reported in previous literature.48 Statistical comparisons of
all nanoparticles indicated that the loading capacity maximum was achieved when 1 to 1 molar
ratio of [IR780][TPB] GUMBOS and HP-β-CD was used for nanoparticle preparation. This
observation is also consistent with results from our in vitro cytotoxicity studies, in which
nanoparticles prepared in this manner demonstrated greatest toxicity towards breast cancer cells
(Table 3.2). Therefore, this optimized CD-[IR780][TPB] nanoGUMBOS prepared using HP-β-CD
was used for further studies. Examination of TEM data indicated that CD-[IR780][TPB]
nanoGUMBOS had a spherical core shell structure with approximate size of 132 ± 23 nm, in
which an inner core with a diameter of approximately 88 nm was observed with a 14 nm thin shell.
Such a shell could be due to the HP-β-CD surface coating (Figure 3.4d); this possibility was further
validated through characterization of CD-based nanoGUMBOS using Fourier-transformed
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infrared spectroscopy (FTIR). As shown in Figure 3.5, the characteristic peak at 3363 cm-1
attributed to O-H stretching from HP-β-CD was observed for these nanoparticles.
(b)

(a)

80

d = 88 ± 17 nm
Frequency

60

40

20

0
30 45 60 75 90 105 120 135 150 165 180 195 210 225 240 255

60

(c)

Diameter (nm)

(d)

d = 132 ± 23 nm

Frequency

40

20

0
30 45 60 75 90 105 120 135 150 165 180 195 210 225 240 255
Diameter (nm)

Figure 3.4. Characterization of particle sizes for [IR780][TPB] nanoGUMBOS and CD[IR780][TPB] NanoGUMBOS using TEM. Each histogram constitutes 200 individual
nanoparticles with a distribution curve overlay as well as a representative portion of a TEM
micrograph (all scale bars represent 500 nm): (a) and (b) [IR780][TPB], (c) and (d) CD[IR780][TPB].

Compound
𝛽-CD
𝛽-CD
HP-𝛽-CD
HP-𝛽-CD

Experimentally
used molar ratio
of GUMBOS and
CD

Calculated molar
ratio of
GUMBOS and
CD in NPs

Drug loading
capacity (%)

MDA-MB-231
IC50 of NPs
(𝜇g/mL)

1:1
1:2
1:1

1.2 ± 0.5

48 ± 1.8

5.8 ± 0.3

0.6 ± 0.1
1.8 ± 0.3
0.58 ± 0.01

32 ± 0.5
51 ± 1.6
27 ± 0.2

9.7 ± 0.1
2.8 ± 0.1
11.3 ± 0.5

1:2

Table 3.2. Characterizations of CD-based nanoGUMBOS fabricated using different molar ratios
of [IR780][TPB] and cyclodextrin including calculated molar ratio, drug loading capacity, and
IC50 values for cultured MDA-MB-231 breast cancer cells.
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Figure 3.5. Infrared Spectra of (a)[IR780][TPB], (b) HP-β-CD, and (c)HP-β-CD/[IR780][TPB]
nanoGUMBOS in the molar ratio of 1:1 of [IR780][TPB] and HP-β-CD.
Evaluation of DLS measurements revealed a narrow size distribution with an average
hydrodynamic size of 142 nm and PDI of 0.11, which is in a good agreement with TEM analysis.
The zeta potential was also examined in PBS at pH 7.4. These CD-based nanoGUMBOS displayed
a zeta potential of -21 mV, which is similar to control nanoGUMBOS. Subsequently, the stability
of CD-[IR780][TPB] nanoGUMBOS was examined by monitoring their hydrodynamic size
change in PBS with time, concentration, and temperature. As presented in Figure 3.6, the size and
PDI had minimal variation under all the tested conditions, indicating excellent stability of CD[IR780][TPB] nanoGUMBOS. For possible applications using in vivo studies, stability in PBS
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containing 10% mouse serum was also evaluated by monitoring the absorbance of nanoparticles
over a 48 h period at 37° C. Note in Figure 3.7, little or no change of the spectrum was identified
with time, further indicating favorable stability of CD-based nanoGUMBOS in the context of
physiological conditions.
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Figure 3.6. Hydrodynamic size and PDI for CD-[IR780][TPB] nanoGUMBOS in 1XPBS with (a)
time and (b) concentration at 25 oC, and (c) temperature, indicating relatively stable nanoparticles.
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Figure 3.7. Absorbance measurements to evaluate stability of nanoGUMBOS in 1XPBS with 10%
mouse serum. Normalized peak absorbance was determined by dividing the peak absorbance after
certain hours by their maximum of peak absorbance.

3.3.3. Complexation Study for Formation of CD-based NanoGUMBOS
CD has been widely demonstrated to accommodate various hydrophobic drugs into their
central cavity and form drug-inclusion complexes for improved drug stability in a biological
environment;

49-50

thus, it is reasonable to hypothesize that our hydrophobic GUMBOS form

complexes with HP-β-CD before further self-assembly into nanoGUMBOS. In order to confirm
this hypothesis, differential scanning calorimetry (DSC) measurements and computational
simulations were both performed to study the complexation between HP-β-CD and hydrophobic
GUMBOS. Figure 3.8a show the DSC thermograms of [IR780][TPB]GUMBOS, HP-β-CD,
physical mixture of GUMBOS and HP-β-CD, and CD-[IR780][TPB] nanoGUMBOS. A small
characteristic endothermic peak at 76.1 oC was observed for [IR780][TPB] GUMBOS, while HPβ-CD showed a broad peak at 54 °C due to dehydration of adsorbed water molecules. The
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thermogram of their physical mixture displayed two well resolved endothermic peaks. One peak
at 76.9 oC is similar to that of pure GUMBOS, while another at 38.5 oC is slightly shifted from the
peak corresponding to HP-β-CD. In contrast, no clear endothermic peak was observed for CDbased nanoGUMBOS, indicating strong interactions between the GUMBOS and HP-β-CD or
formation of the inclusion complex. Similar results were also obtained with other previously
reported CD complexes. 51-52
Docking and molecular dynamics (MD) simulations were performed to study possible
complexation of each counter-ion of [IR780][TPB] GUMBOS with HP-β-CD due to their
lipophilicities. Such data may provide further insight into interactions of GUMBOS and HP-β-CD.
The stable binding complexes (Figure. 3.8b iii) with highest fitting score from docking studies
were used as initial structures in MD simulations. Figure 3.8b(iv) shows a separation of TPB from
HP-β-CD during MD simulations, indicating an unstable state of the complex. Weak binding of a
similar system (TPB and β-CD) was also observed in the experiment as previously reported.53 In
contrast, the complex of IR780 and HP-β-CD was found to be stable during MD simulations
(Figure 3.8b(ii)). The free energy of binding for the IR780 and HP-β-CD complex was calculated
to be -6.70 kcal/mol by using a MM/GBSA approach (Table 3.3).54-55 Using both experimental
and computation approaches, formation of a stable complex of HP-β-CD and GUMBOS was
demonstrated, which thus elucidates the enhanced stability of CD-based nanoGUMBOS in
aqueous medium as compared to control nanoGUMBOS.
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Figure 3.8. (a) DSC thermograms of [IR780][TPB]GUMBOS, HP- -CD, their physical mixture,
and CD-[IR780][TPB] nanoGUMBOS. (b) Initial structures of (i) IR780/ HP-β-CD complex and
(iii) TPB/ HP- -CD complex from docking studies and their typical snapshots (ii &iv) from
production of MD simulation trajectories. Water molecules and counter ions are omitted for clarity.
Gray sticks represent HP-β-CD molecules, green for IR780 and red for TPB.
Table 3.3. MM/GBSA binding free energy and energy components (kcal/mol) for the
complexation of cationic IR780 with HP-β-CD.
IR780 & HP-𝛽-CD
ΔEVDW
ΔEELE
ΔEGB
ΔESURF
ΔGGAS
ΔGSOL
TS
ΔGBIND

-45.49 ± 2.42
-1.62 ± 3.43
17.58 ± 3.58
-5.04 ± 0.22
-47.11± 4.49
12.54 ±3.53
-27.87±2.73
-6.70
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3.3.4. Photophysical Properties of CD-based NanoGUMBOS
The photophysical properties of CD-[IR780][TPB] nanoGUMBOS in water were also
investigated. As shown in Figure 3.9a, the CD-[IR780][TPB] nanoGUMBOS displayed a broad
absorption spectrum in the near infrared (NIR) region from 600 nm to 900 nm, indicating a
potential PTT effect with NIR irradiation. A similar spectrum was also obtained for the control
nanoGUMBOS. In comparison with that of free IR780, red-shifted absorption spectra of both
nanoGUMBOS were observed. For example, the absorption maximum of CD-[IR780][TPB]
nanoGUMBOS was at 790 nm with a shoulder at 728 nm. In contrast, free IR780 displayed an
absorption spectrum with a peak at 774 nm and a shoulder at 710 nm. Such red shift observed in
the absorption spectrum of each nanoGUMBOS relative to the free IR780 was attributed to
formation of J-aggregation of these nanoparticles.56 Moreover, the fluorescence emission spectrum
showed an intense fluorescence signal in the NIR region with peak emission at 800 nm (Figure
3.9b). This wavelength would allow deep tissue NIRF imaging in vivo and provide real-time
fluorescence guidance for PTT applications.57-58 Interestingly, the photo-stabilities of both
nanoGUMBOS were found to be significantly improved in comparison with the parent compound.
As shown in Figure 3.9c, a significant reduction in emission maxima was observed for IR780 with
irradiation time. In contrast, no change of emission maxima was observed for either [IR780][TPB]
nanoGUMBOS or CD-[IR780][TPB] nanoGUMBOS. This observation is important when
considering the use of these nanoGUMBOS as theranostic agents. The photothermal property of
these nanoGUMBOS was also studied by measuring the temperature increase of nanoparticle
solution under 808 nm NIR laser irradiation, and results were compared with the parent dye. As
observed in Figure 3.9d, the parent dye displayed a rapid increase in temperature by approximately
9.4° C and reached a temperature maximum after 150 seconds of irradiation. In contrast,
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[IR780][TPB] nanoGUMBOS and CD-[IR780][TPB] nanoGUMBOS displayed a significantly
higher temperature increase by approximately 16.8 °C and 18.0 °C respectively after 10 min of
irradiation. This enhanced photothermal property of nanoGUMBOS can be correlated with their
enhanced photo-stabilities as described above. These results revealed that nanoGUMBOS could
be superior to IR780 and may serve as more effective photothermal agents. In addition,
examination of the size of both nanoGUMBOS before and after irradiation were performed using
DLS measurements. For example, size distributions of both nanomaterials were narrow with PDI,
i.e. less than 0.2 before laser irradiation. In contrast, the size distribution became broader and
multiple peaks appeared after laser irradiation (Figure 3.10). The calculated PDI for [IR780][TPB]
nanoGUMBOS and CD-[IR780][TPB] nanoGUMBOS following laser irradiation were 0.36 and
0.47, respectively. These observations suggest dissociation of the nanoGUMBOS upon laser
irradiation; this effect may help to facilitate drug release, thus activating the chemotherapeutic
activity of IR780 at the tumor site. A similar phenomenon was observed in our previous study, in
which dissociation of rhodamine-based nanoGUMBOS in the acidic pH environment of lysosomes
activated the toxicity of rhodamine in cancer cells.24
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Figure 3.9. (a) Absorption spectra, (b) emission spectra, and (c) photostability of [IR780][I],
[IR780][TPB] nanoGUMBOS, and CD-[IR780][TPB] nanoGUMBOS in deionized water, (d)
Thermal curves of [IR780][I], [IR780][TPB] nanoGUMBOS and CD-[IR780][TPB] (100 µM
IR780 equivalent) after 808 nm laser irradiation (0.5 W/cm2).
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3.3.5. In vitro Chemo/Phototheramal Therapeutic Effects of NanoGUMBOS
In vitro chemotherapeutic effects of the nanoGUMBOS were firstly studied by assessment
of their cytotoxicity towards three breast cancer cell lines (MDA-MB-231, MCF-7, and Hs578T)
as well as a normal breast epithelial cells (HMEC) and a myoepithelial cell line (Hs578Bst). As
determined by MTT assay, significant cytotoxicity towards the breast cancer cell lines was
observed

upon

treatments

of

[IR780][TPB]

nanoGUMBOS

and

CD-[IR780][TPB]

nanoGUMBOS while minimum cytotoxicity towards normal cell lines was observed (Figures
3.11b&c). For example, treatment of MDA-MB-231 and Hs578T cancer cells with [IR780][TPB]
nanoGUMBOS and CD-[IR780][TPB] nanoGUMBOS led to almost eradication of cancer cells at
a concentration at 50 µg/mL, while greater than 75% cell viability of normal cells (HMEC and

98

Hs578Bst) was still maintained. However, it was observed that the parent dye IR780 inhibited cell
proliferation of both normal and breast cancer cell lines in a dose-dependent manner (Figure 3.11a).
Similar results were observed for the IR780 dye in prostate cancer and normal cells as reported in
previous literature.8 In support of their potential chemotherapeutic application, analyses of these
results demonstrated that nanoGUMBOS formulation greatly improved the selective toxicity
towards cancer cells with reduced toxicity towards normal cells as compared with the parent dye.
In addition, the IC50 data were calculated and compared (Figure 3.11d). It is interesting to note that
the two metastatic triple-negative (ER-, PR-, HER2-) breast cancer cell lines (MDA-MB-231 and
Hs578T) were more sensitive towards the nanomaterials than the estrogen-responsive MCF-7
cancer cell line, as indicated by the smaller IC50 values. This result also suggests that our
nanoGUMBOS can be further investigated as a potential chemotherapeutic agent for treating
triple-negative breast cancer.
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Figure 3.11. Cell viability of breast cancer cell lines (MDA-MB-231, Hs578T, and MCF-7) and
breast normal cell lines (HMEC and Hs578Bst) upon treatment with (a) [IR780][I], (b)
[IR780][TPB] nanoGUMBOS, and (c) CD-[IR780][TPB] nanoGUMBOS for 48 h. (d) IC50 values
of all compounds for cultured cancer cell lines and normal cell lines. “---” represent not calculated
due to the minimum toxicity.
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Cell viability studies of these nanomaterials under laser irradiation were conducted using
two breast cancer cell lines (MDA-MB-231 and Hs578T) to examine in vitro PTT effects. As
observed in Figure 3.12a, no significant difference in the cytotoxicity of the parent dye was
observed between treatments with irradiation and without irradiation. This can be attributed to the
low uptake of parent dye into the cells. In contrast, both [IR780][TPB] nanoGUMBOS and CD[IR780][TPB] nanoGUMBOS displayed significantly higher cytotoxicity even at low
concentrations in MDA-MB-231 cancer cells (Figures 3.12b and 3.12c) and Hs578T cancer cells
(Figure 3.13) with 808 nm laser irradiation relative to cytotoxicity without laser irradiation.
Moreover, laser irradiation treatment with CD-[IR780][TPB] nanoGUMBOS led to the highest
cytotoxicity towards cancer cells among all materials tested. For instance, treatment with 0.39
µg/mL of CD-[IR780][TPB] nanoGUMBOS with laser irradiation resulted in a decreased cell
viability of 49.5%, whereas [IR780][TPB] nanoGUMBOS and the parent dye yielded cell
viabilities of 84.6% and 88% respectively at the same concentration (Figure 3.12). In this case, the
enhanced cancer-killing activity of CD-[IR780][TPB] nanoGUMBOS may be attributed to
synergetic effects from their enhanced chemotherapeutic behaviors and more efficient
photothermal properties as compared to [IR780][TPB] nanoGUMBOS and the parent dye.
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Figure 3.12. Cell viability of MDA-MB-231 cancer cell lines after incubation with (a) [IR780][I],
(b) [IR780][TPB], and (c) CD-[IR780][TPB] for 24 h with and without laser irradiation. Statistical
significance was assessed using a two-way ANOVA test; (**P ≤ 0.05, ***P ≤ 0.001, ****P ≤
0.0001)
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Figure 3.13. Cell viability of Hs578T cell lines after being incubated with nanoGUMBOS for 24
h with/without laser irradiation. Statistical significance analysis was assessed by use of GraphPad
via two-way ANOVA test (**P ≤ 0.05, ***P ≤ 0.001, ****P ≤0.0001).
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3.3.6. Cellular Uptake and Localization
In order to further understand enhanced chemo/photothermal activities of CD[IR780][TPB] nanoGUMBOS, cellular uptake was examined and determined using a previously
reported method.10 As observed in Figure 3.14a, significantly enhanced uptakes of [IR780][TPB]
nanoGUMBOS and CD-[IR780][TPB] nanoGUMBOS were observed as compared to the parent
dye. This indicates the role of counter-ion variation on facilitating internalization of these
nanomaterials. Similar results were observed in our previously reported nanoGUMBOS.10
Moreover, examination of these results indicated that the presence of CD further promoted
internalization of CD-[IR780][TPB] nanoGUMBOS with the greatest uptake relative to the other
two materials. This correlates well with the enhanced chemo/photothermal activities of CD[IR780][TPB] nanoGUMBOS that were observed.
Given that cationic IR780 has been shown to be a mitochondrial toxin, effects of using
counter-ion variations of [IR780][TPB] and CD complexing of [IR780][TPB] on mitochondrial
localization were studied. These studies may aid in further elucidation of the observed therapeutic
behavior, since the mitochondria plays an important role in the regulation of cell death.59 Colocalization of fluorescence from nanoGUMBOS and MitoTracker Green are displayed in Figure
3.14b. It is important to note a significant yellow overlay resulting from the red fluorescence of
nanoGUMBOS and green fluorescence of MitoTracker Green for both [IR780][TPB]
nanoGUMBOS and CD-[IR780][TPB] nanoGUMBOS in the merged images. The yellow overlay
indicates their mitochondria co-localization. From these results, it is concluded that subcellular
localization of [IR780][TPB] nanoGUMBOS and CD-[IR780][TPB] nanoGUMBOS were similar
for counter-ion variation and CD complexing.
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Figure 3.14. (a) Cellular uptake of IR780 after incubation of [IR780][I], [IR780][TPB]
nanoGUMBOS and CD-[IR780][TPB] nanoGUMBOS in MDA-MB-231 cancer cells for 4h. (b)
Co-localization of [IR780][TPB] nanoGUMBOS and CD-[IR780][TPB] NPs with MitoTracker
Green dye imaged by use of a fluorescence microscope. All scale bars on the fluorescence
microscopy images represent 25 µm.
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3.3.7. In vivo NIRF Imaging and Tumor Targeting Behavior
In vivo NIRF imaging of both control nanoGUMBOS and CD-based nanoGUMBOS was
performed using an MDA-MB-231 tumor xenograft model. This allows for investigation of their
biodistribution, as well as determination of tumor localization, which is an important criterion for
PTT applications. All compounds were intravenously injected into tumor-bearing mice and imaged
at several time points. As shown in Figure 3.15a, mice treated with [IR780][TPB] nanoGUMBOS
displayed a gradual increase in fluorescence signal over the entire body with time. After 24h of
post-injection, a preferential accumulation at the tumor site was observed in contrast to other organ
sites. This tumor accumulation further increased with time, up to 72 h, which implied long-term
maintenance of these nanoGUMBOS in the body of mice. In mice treated with CD-[IR780][TPB]
nanoGUMBOS, these nanoparticles preferentially accumulated at the tumor site after 6 h,
indicating more rapid delivery into tumor tissues as compared to [IR780][TPB] nanoGUMBOS
(Figure 3.15a). This observation was also consistent with in vitro cellular uptake kinetics, in which
CD-[IR780][TPB] nanoGUMBOS displayed more rapid uptake than the control nanoGUMBOS
(Figure 3.16). Subsequently, the fluorescence signal at the tumor site exhibited a continual increase
up to 72 h, with a slight reduction afterwards, possibly due to metabolism and excretion from the
body. In comparison with most of the IR780 injected doses that displayed a rapid clearance within
24 h after intravenous injection in reported literature,18 both [IR780][TPB] and CD-[IR780][TPB]
nanoGUMBOS displayed a prolonged drug retention at the tumor site. Thus, our nanoGUMBOS
allow tumor monitoring using NIRF imaging as well as show great potential for drug delivery.
Ex vivo evaluation of organs excised at 120 h of post-injection was also performed to gain
better insight into biodistribution of nanoparticles (Figures 3.15b&c). For our nanoGUMBOS
treated mice, significantly higher fluorescence intensity was observed at the tumor tissue compared
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to other organs. Interestingly, CD-[IR780][TPB] nanoGUMBOS also displayed enhanced tumor
accumulation as compared to [IR780][TPB] nanoGUMBOS, as evidenced by significantly
stronger fluorescence intensity in tumor tissue (Figure 3.15c). Analyses of these results further
demonstrated that use of CD for nanoGUMBOS preparation could effectively enhance drug
bioavailability in vivo as well as promote targeted accumulation of nanoGUMBOS in the tumor
region without introduction of a targeting moiety.
Since some accumulations at other organs were also observed in the ex vivo images, the
potential toxic side effects of both nanoGUMBOS were evaluated. At 14 days after injection of
[IR780][TPB] and CD-[IR780][TPB] nanoGUMBOS with two doses (2 mg/kg [IR780][TPB]
equivalent per dose), the mice were euthanized and major organs were collected for histological
analysis using hematoxylin and eosin (H&E) staining. As observed in Figure 3.15d, no noticeable
histological changes in major organs of mice were observed as compared with organs from healthy
mice, suggesting nanoGUMBOS are nontoxic towards normal tissues at doses used. These results
are also in agreement with their selective toxicity in vitro as described earlier. Thus, in comparison
with the parent dye, which displayed severe and acute toxicity at a dose of 2 mg/kg as previously
reported,19 our nanoparticles could be safer theranostic agents than traditional IR780 in imagingguided PTT experiments.
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Figure 3.15. (a) In vivo NIRF imaging of [IR780][TPB] nanoGUMBOS and CD-[IR780][TPB]
nanoGUMBOS at different time points. (b) Ex vivo images of major organs and tumors after postinjection of nanoGUMBOS for 120 h. (c) Fluorescence intensities measured from ex vivo images
of major organs and tumors. (d) H&E staining images of major organs for histology analysis.
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Figure 3.16. Kinetic study of cellular uptake after incubation of 12.5 µg/mL of [IR780][I],
[IR780][TPB] nanoGUMBOS, and CD-[IR780][TPB] nanoGUMBOS in MDA-MB-231 cancer
cells. Fluorescence peak intensities were recorded and normalized by dividing the peak intensity
at that time point by its initial peak intensity.
3.3.8. In vivo Chemo/Photothermal Therapeutic Effect
Motivated by highly selective accumulation, long-term retention within tumor tissue, and
biocompatiblity

of

CD-[IR780][TPB]

nanoGUMBOS,

I

further

evaluated

in

vivo

chemo/photothermal therapeutic efficacy of this nanoGUMBOS. The MDA-MB-231 tumorbearing mice were randomly divided into four groups with six per group, subsequently treated with
PBS, PBS plus laser, CD-[IR780][TPB] nanoGUMBOS, and CD-[IR780][TPB] nanoGUMBOS
plus laser. In these studies, laser irradiation was applied for 2 mins at a power density of 2W/cm2
using a 808 NIR laser. Upon laser irradiaiton, photothermal effects were examined using an
infrared thermal camera. As shown in Figures 3.17a and 3.17b, the tempearature of tumors treated
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with PBS only increased by approxiamtely 5 oC and reached a temparature plateau at 38.5 oC. In
comparsion, tumors treated with nanoGUMBOS displayed a significantly enhanced tempearture
increase by approxiamtely 16 oC, and maximium tempearture reached was 55.5 oC, which is
beyond the threshold that induces damage of tumor vessles and tumor cells.60 Such significant
tempearature increase confirmed the high PTT effects of CD-based nanoGUMBOS in vivo.
In additon, tumor volumes from all groups were monitored and recorded for the
examination of the therapeutic effects of CD-[IR780][TPB] nanoGUMBOS. As shown in Figure
3.17c, the tumor volume from the PBS group grew rapidly, and reached nealy 6 times their intial
size by day 18. In comparison, tumors treated with CD-[IR780][TPB] nanoGUMBOS displayed
a significanlty slower growth from day 10 to day 18 than the PBS-treated control group after
employing statistic analysis, indicating the intrinsic antitumor effects of CD-[IR780][TPB]
nanoGUMBOS, consistent with our in vitro studies. More importantly, tumor volume of mice
treated with CD-[IR780][TPB] plus laser were significantly reduced as compared to that of the
other three groups. This observation can be explained via a synergetic chemo/photothermal
theraputic effect of CD-[IR780][TPB] upon laser irradiation.
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Figure 3.17. In vivo photothermal therapy. (a) Infrared thermographs of tumor-bearing mice under
808 nm laser irradiation at a power density of 2W/cm2. (b)Temperature profiles of irradiated
tumors as a function of irradiation time. (c) Relative tumor volume (RTV) of four groups of tumorbearing mice with six mice per group after various treatments. RTV was calculated using the
formula: RTV= Vx/V0, where Vx and V0 is the volume measured at day x and injection day,
respectively. Laser irradiation for 2 min at a power density of 2W/cm2 was applied at 72 h of postinjection of PBS and CD-[IR780][TPB] (3mg/kg), designated as day 3. Data were shown as mean
± SD.*P < 0.05.
3.4. Conclusion
In this study, I report fabrication, characterizations, and multifunctional applications of
NIR nanoGUMBOS as theranostic agents for enhanced chemo/photothermal anticancer effects.
Using counter-ion variations of a NIR dye, IR780, and CD complexing strategies, CD-based NIR
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nanoGUMBOS were successfully fabricated to achieve an average size of approximately 132 nm.
The resulting CD-[IR780][TPB] nanoGUMBOS displayed a core-shell structure with improved
stability in comparison to [IR780][TPB] nanoGUMBOS without CD, providing several
advantages for biological applications. In addition, CD-based nanoGUMBOS showed excellent
photo-stability and photo-thermal properties under NIR irradiation, and allowed for enhanced PTT
application. Additional in vivo NIRF imaging results demonstrated preferential accumulation of
CD-[IR780][TPB] nanoGUMBOS at the tumor site with excellent tumor retention ability due to
EPR effects. Most importantly, remarkable chemo/photothermal therapeutic effects were achieved
using CD-[IR780][TPB] nanoGUMBOS for cancer treatment both in vitro and in vivo, without
inducing undesirable toxicity for the test dose. Thus, based on these results, it is concluded that
CD-based nanoGUMBOS show great potential for use as cancer theranostic agents.
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CHAPTER 4. MULTIFUNCTIONAL PEGYLATED NANOGUMBOS FOR DRUG
DELIVERY
4.1. Introduction
Despite significant progress for discovery of cancer therapeutics in recent years, there
remain many challenges that hinder their further clinical applications. One of the major challenges
is associated with concerns about hydrophobic anticancer drugs. As a typical example, paclitaxel
(PTX) is a well-known antineoplastic drug that has shown excellent chemotherapeutic effects
against various tumors such as breast cancer, lung cancer, and ovarian cancer.1 However, this drug
molecule is extremely hydrophobic with poor aqueous solubility of 0.3 µg/ml, thus making
formulation difficult.2 Herein, various nanoscale drug delivery platforms, also referred to as
nanocarriers have been recently proposed and investigated to improve the formulation of such
hydrophobic drug molecules. These nanocarriers include polymeric micelles3-5, liposomes6-7, and
other nanoparticles8-9, some of which have already been approved for clinical trials such as
Genexol-PM.5 This is a micellar formulation of PTX developed by Samyang pharmaceutics using
an amphiphilic diblock copolymer (mPEG-PDLLA) as solubilizer. As compared with
conventional PTX formulation using Cremophor EL, this nanocarrier has resulted in enhanced
solubility, minimum hypersensitivity, and ultimately improved drug efficacy.2, 10
Currently, development of multifunctional therapeutic nanoparticles has attracted more and
more attentions for drug delivery. These multifunctional nanoparticles can simultaneously
accommodate imaging, tumor targeting, and therapeutic modalities to achieve imaging-guided
drug delivery in a targeting way.11-12 In this scenario, the imaging modality allows for real-time
monitoring of the whole drug delivery process, which can help physicians to customize the
treatment for each individual patient. Particularly, near infrared fluorescence (NIRF) imaging has
gained tremendous interests in these biomedical imaging applications due to low cost and high
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sensitivity.13-14 The tumor targeting property is responsible for specific delivery of therapeutic
agents to the tumor site, thus minimizing damage to healthy tissues.15 On the other hand, such
nanoparticles can also allow to deliver multiple therapeutic agents for combination therapy,
resulting in an enhanced therapeutic efficacy.16 Therefore, these multifunctional nanocarriers
provide an opportunity to further improve current drug delivery technology.
Our research group has recently developed a group of uniform materials based on organic
salts (GUMBOS) for a variety of biomedical applications. Examples include imaging,
chemotherapy, and antimicrobial agents etc.17-20 GUMBOS are solid-phase analogs of ionic liquids
(ILs) that are typically synthesized using a simple ion exchange reaction. With counter-ion
variation, GUMBOS are observed to display broadly tunable properties including melting point,
solubility, hydrophobicity, and toxicity etc.21 Thus, task-specific or multifunctional GUMBOS can
be designed using the flexible paring of constituent ions. For example, in my previous study, I
have reported an array of GUMBOS, followed by conversion into nanoparticles, i.e.
nanoGUMBOS, for enhanced selective toxicity towards cancer cells.22 These GUMBOS combined
a NIRF cation, IR780, with different inert anions that have varying compositions and
hydrophobicity. Changing anion of these GUMBOS resulted in variations in their melting point,
hydrophobicity, and optical properties, while core features of IR780 cation were still retained.
These features include strong NIR fluorescence, mitochondria targeting, and cancer killing
activities. Most importantly, such anion modification enhanced toxicity of IR780 towards cancer
cells with negligible toxicity towards normal cells, making these GUMBOS more favorable for
tumor targeting applications than traditional IR780.
Inspired by promising tunable properties of IR780-based GUMBOS for biomedical
applications, herein I developed a series of multifunctional nanocarriers using these GUMBOS for
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simultaneous delivery of PTX and bio-imaging applications. Synthesis of such nanocarriers also
involved the use of a PEGylation approach to modify GUMBOS. This approach has been reported
with several unique advantages for preparation of nanocarriers, including stabilizing nanocarriers
in aqueous system, prolonging circulation time, and increasing drug accumulation in the tumor
site.23-24 To use these advantages of PEGylation, hydrophobic GUMBOS were converted into an
amphiphilic PEGylated GUMBOS by linking a hydrophilic PEG segment to the IR780 cation. The
resultant amphiphilic GUBMOS could interact with hydrophobic PTX and self-assemble into
drug-loaded nanoGUMBOS. Many factors play an important role in the self-assembly of
amphiphilic molecules including hydrophobic interactions, hydration, and hydrogen bonding, of
which hydrophobic interactions have shown predominant impacts.25 In our case, the GUMBOS
moiety can be easily tuned to control hydrophobic interactions using anion variation, thus affecting
both self-assembly and drug loading processes. Following synthesis of an array of drug-loaded
nanoGUMBOS, their characterizations were examined with respect to size, morphology, stability,
drug encapsulation efficiency, drug release behavior, and NIRF imaging property. Additionally,
in vitro cytotoxicity and cellular uptake studies of nanoGUMBOS were performed to evaluate their
capability for drug delivery.
4.2. Materials and Methods
4.2.1. Materials
PEG 2000-SH was purchased from Laysan Bio InC. paclitaxel, IR780 iodide (98%),
trimethylamine(TEA), bis(2-ethylhexyl) sulfosuccinate (AOT) sodium salt (≥99%), lithium
bis(trifluoromethane)sulfonamide (NTF2), and bovine serum albumin (BSA) were all purchased
from Sigma-Aldrich. Lithium bis(perfluoroethylsulfonyl)imide (BETI) was obtained from Ionic
Liquids Technologies (Tuscaloosa, AL). Chloroform (CHCl3), methanol (MeOH), Acetonitrile
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(ACN), and dichlormethane (DCM) were purchased from VWR. Cell viability MTT (3-[4, 5Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium

bromide)

were

purchased

from

Promega

Corporation (Madison, WI). MitoTracker and LysoTracker dyes were purchased from Molecular
Probes (Eugene, OR).
4.2.2. Synthesis of PEGylated IR780 GUMBOS
According to a previously reported protocol, IR780-based GUMBOS were firstly
synthesized using a metathesis reaction.22 Briefly, 1 to 1.2 molar ratio of IR780 iodide and the
counter-anion salts were dissolved in a mixture of DCM and deionized water (2:1, v/v). This
mixture was stirred for 48 h at room temperature. Subsequently, the water layer was decanted, and
the organic layer was washed with fresh water several times to remove any byproducts. Finally,
dried products were obtained by removal of organic solvents in vacuo and subsequent freezedrying. Formation of GUMBOS was confirmed by use of ESI-MS.
PEGylated GUMBOS (PEG-GUMBOS) were synthesized via a thiol substitution
reaction.26 For example, in order to synthesize PEG-[IR780][BETI] GUMBOS, PEG2000-SH
(120 mg, 0.060 mmol), [IR780][BETI] GUMBOS (50 mg, 0.054 mmol) and TEA (30 µL, 0.216
mmol) were mixed in 50 ml of CHCl3 and stirred for 48 h at room temperature under N2
atmosphere. This reaction was monitored by use of thin layer chromatography with CHCl3/MeOH
(9:1, v/v) as the eluting solvent, and products with higher polarity were observed. Subsequently,
the solvent was blowing-dried using N2, and a silica gel based column chromatography using
CHCl3/MeOH (100:0 to 70:30, v/v) eluent was performed to purify the product. Finally, the
organic solvent was removed in vacuo to yield the product as a dark green solid. This product was
characterized by proton nuclear magnetic resonance (1H NMR) spectroscopy and electrospray
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ionization mass spectrometry (ESI-MS). A similar synthetic procedure was employed to synthesize
PEG-[IR780][I], PEG-[IR780][NTF2] and PEG-[IR780][AOT].
4.2.3. Preparation of PEGylated IR780 NanoGUMBOS Loaded with PTX
PTX loaded PEG-IR780 (PTX/PEG-IR780) nanoGUMBOS were prepared using a thin
film hydration method similar to the reported literature with slight modifications.27 For example,
10 mg PEG-[IR780][BETI] and 1 mg PTX were firstly mixed in a vial with 5 ml of acetone.
Following that, the organic solvent was removed by rotary evaporation, leading to formation of a
homogeneous thin film. Then the thin film was hydrated using 2 ml of 1X PBS (pH 7.4), followed
by ultrasonication for 10 min using a bath sonicator. Finally, PTX loaded PEG-[IR780][BETI]
nanoGUMBOS solution was filtered using a 0.45 µm Nylon filter and further freeze-dried for longterm storage. Other PTX loaded nanoGUMBOS were also obtained by following the same
procedures.
4.2.4. Characterization of PTX/PEG-IR780 NanoGUMBOS
The size and morphology of these PEG-IR780/PTX nanoGUMBOS at dried state were
determined using transmission electron microscopy (TEM). All TEM micrographs were captured
using an LVEM 5 transmission electron microscope (Delong America, Montreal, Canada). The
resulting nanoparticles were also characterized by dynamic light scattering (DLS) analysis using
a Malvern Zetasizer Nano-ZS (Malvern instruments, UK) at 25 oC regarding their hydrodynamic
size, zeta potential, and stability in 1X PBS solution. In addition, encapsulation efficiency (EE) of
each PEG-IR780 nanoGUMBOS and their drug contents (DC) were determined using PTX
calibration curve, which was obtained using a high-performance liquid chromatography (HPLC)
system comprised of a 2489 UV/Vis detector (Waters, Milford MA). In this case, a reverse-phase
C18 column (4.6 × 100 mm) and ACN/H2O (70:30, v/v) as mobile phase were used. The flow rate

122

was set to be 1 mL/min, and UV detection was set at 227 nm. EE (%) was then calculated by
dividing the amount of PTX loaded in the nanoGUMBOS by the total amount of PTX used, while
DC (%) was determined by dividing the amount of PTX loaded in the nanoGUMBOS by the total
amount of nanoGUMBOS with PTX loaded.
4.2.5. Drug Release Study
The drug release behavior of each PTX/PEG-IR780 nanoGUMBOS was evaluated using a
dialysis tube technique. Briefly, 100 µL of each nanoGUMBOS in 1XPBS (pH 7.4) at a
concentration of 2mg/mL was added into eight mini dialysis devices (MWCO 10kDA) and tightly
capped. All eight dialysis devices were then suspended in 1L of 1XPBS at pH 7.4 and placed in a
shake incubator at 37 oC. At each time point, 60 µL of nanoGUMBOS were withdraw from one of
the dialysis devices and diluted by mixing with 140 µL of acetonitrile. Then, the concentration of
PTX in diluted aliquot was determined using HPLC technique under conditions similar to these
described in the previous section. Subsequently, the unreleased concentration of PTX in the
dialysis device were calculated based on the dilution factor, and the final drug release % was
determined using the following equation:
𝐷𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 % = 1 −

𝑐𝑜𝑛𝑐. 𝑜𝑓 𝑃𝑇𝑋 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑖𝑎𝑙𝑦𝑠𝑖𝑠 𝑑𝑒𝑣𝑖𝑐𝑒
𝑐𝑜𝑛𝑐. 𝑜𝑓 𝑃𝑇𝑋 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑖𝑎𝑙𝑦𝑠𝑖𝑠 𝑑𝑒𝑣i𝑐𝑒

<
<>

×100%

4.1

All the release experiments were performed in triplicate and the results were presented as the
average data with standard deviations.
4.2.6. Protein Adsorption Study
Absorption spectroscopy was used to evaluate interactions between PEG-IR780
nanoGUMBOS and proteins such as BSA. In brief, BSA solutions in 1XPBS (pH 7.4) at different
concentration were prepared freshly prior to further study. NanoGUMBOS in PBS were then
mixed with BSA solution, resulting in a final nanoGUMBOS concentration of 20 µg/mL. This
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mixture was then vigorously shaken and incubated for 1 h at room temperature before absorption
measurements.
4.2.7. Cell Culture
In vitro cell studies were performed using the hormone-independent human breast
adenocarcinoma (MDA-MB-231, ATCC No.HTB-26), human breast carcinoma (Hs578T, ATCC
HTB-126), and human mammary epithelia cells (HMEC, ATCC PCS-600-010) obtained from the
American Tissue Culture Collection (ATCC, Manassas, VA). All cell lines were cultured in a
humidified incubator at 37° C with 5% CO2 and grown to confluence as described by ATCC
protocol specifications before use in further experiments.
4.2.8. In vitro Cytotoxicity Studies
In vitro cytotoxicity of PTX/PEG-IR780 nanoGUMBOS was evaluated on MDA-MB-231,
Hs578T, and HMEC cell lines by use of MTT assay. Briefly, a 96-well flat-bottomed plate was
seeded with approximately 5000 cells per well, and cells were allowed to grow overnight for
adherence. Then old cell medium was removed and free PTX or PTX/PEG-IR780 nanoGUMBOS
with different concentrations were introduced into cells. After 24 h of incubation, cells were
washed twice with fresh cell media, and 18 µL of MTT was added for an additional 2 h of
incubation. Subsequently, 100 µL of stop buffer solution was added to solubilize the purple
formazan crystals, of which peak absorbance at 570 nm was determined using a microplate reader
(PlateReader AF2200, Eppendorf). Cell viability was then calculated as the percentage of the ratio
of absorbance from treated cells and absorbance of untreated cells (control) normalized to 100%
cell viability. IC50 representing the half-maximum inhibitory concentration was also determined
using the GraphPad Prim 7 software (GraphPad Software; La Jolla, CA, USA) through non-linear
regression with least square fit. All measurements were performed in triplicates.
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4.2.9. Subcellular Localization
Fluorescence microscope (Leica, TCS SP5, Mannheim, Germany) was used to study the
subcellular localization of PTX/PEG-IR780 nanoGUMBOS. Briefly, MDA-MB-231 cancer cells
were plated in a 35 mm glass bottomed petri dish at a density of 2×105 cells/dish and incubated
overnight at 37° C. Cells were then treated with 15 nM of LysoTracker for 20 min. Subsequently,
cells were washed with fresh cell media, and incubated with 10 nM of MitoTracker dye for 30 min,
which allows to stain mitochondria. Cells were then washed again, followed by incubation of 12.5
µg/mL of PTX/PEG-IR780 nanoGUMBOS for 0.5h. Finally, cells were washed with 1XPBS (pH
7.4) several times and examined using a 40X water dipping objective on the fluorescence
microscope.
4.2.10. Statistical Analysis
The significance of difference was evaluated by use of a two-way ANOVA analysis
provided by the statistical package of the GraphPad Prim 7 software. Data were considered
statistically significant when p<0.05.
4.3. Results and Discussions
4.3.1. Synthesis and Characterization of PEGylated IR780 GUMBOS
GUMBOS were firstly synthesized via an ion exchange reaction between [IR780][I] and
[Na][NTF2], [Li][BETI], or [Na][AOT] according to the previously reported literature.22 The
detailed procedures were described in the experimental section. The obtained products were
characterized using ESI-MS at both positive and negative mode for confirmation of molecular
mass of the desired cations and anions (Table 4.1). Analyses of results from ESI-MS demonstrated
successful formation of all IR780 GUMBOS. In addition, hydrophobicity was gauged using
octanol water partition coefficient (logP), which can provide a better insight into understanding of
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nanoparticle formation as well as drug loading. Examination of their logP indicated [IR780][AOT]
is most hydrophobic, followed by [IR780][BETI], [IR780][NTF2], and [IR780][I] (Table 4.2). As
expected, GUMBOS displayed a variable hydrophobicity with counter-ion variation.
Table 4.1. ESI-MS analysis of all GUMBOS.
positive mode
GUMBOS

negative mode

Theoretical mass

Actual mass

Theoretical mass

Actual mass

(m/z)

(m/z)

(m/z)

(m/z)

[IR780][NTF2]

540.2

539.3

280.1

279.9

[IR780][BETI]

540.2

539.2

378.1

379.9

[IR780][AOT]

540.2

539.3

421.6

421.2

Table 4.2. Octanol/water partition coefficients (logP) of all GUMBOS.
GUMBOS

logP

[IR780][I]

0.93 ± 0.07

[IR780][NTF2]

1.15 ± 0.05

[IR780][BETI]

1.3 ± 0.1

[IR780][AOT]

1.55 ± 0.08

To synthesize PEGylated IR780 GUMBOS, PEG2000-SH was used to conjugate with
IR780 cation via a thiol substitution reaction (Figure 4.1). In this scenario, the chloride on the
central cyclohexenyl ring of IR780 was substituted by the thiol group in PEG2000-SH.
Examination of 1H NMR and ESI-MS spectra confirmed the structure of PEGylated GUMBOS.
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An example is shown in Figures 4.2 and 4.3, the 1H NMR spectrum of PEG-[IR780][BETI]
exhibited both IR780 peaks [δ 0.97(k), δ 1.7(d), δ 1.79(j) δ 2.65(a), δ 4.17(i), δ 6.31(c), δ 7.26 (b),
δ7.43−8.77 (benzyl group, e−h)] and PEG peak [δ 3,51(l)], indicating PEG was successfully added
to IR780 via thiol substitution. Besides, the mass spectrum of the product displayed a center of
peak at m/z of 2313 at positive mode, which is in a good agreement with the theoretical value of
PEG2000-IR780 (Figure 4.3). Additionally, no peak corresponding to IR780 in ESI-MS spectrum
was detected at positive mode, further confirming the successful PEGylation of IR780.
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Figure 4.1. Synthesis of PEGylated IR780 GUMBOS.

127

O

H 3C

O

O
S OO

CH3

a

N
CH3
CH3

b

S

X-

O

d
c H3C CH3
e
N+

i

h

j

l

d

f

CH3

H2O

g

solvent

k

n
CH3

l

k

e,f
h

g
b

i

c

Figure 4.2. 1HNMR spectrum of PEG-[IR780][BETI] in DMSO-d6.

Figure 4.3. ESI-MS of PEG-[IR780][BETI].
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4.3.2. Preparation and Characterization of PTX/PEG-IR780 NanoGUMBOS.
Given that PEG-IR780 GUMBOS possess an amphiphilic structure, nanoparticles could be
formed in aqueous solution through self-assembly mechanism, similar to formation of micelles. In
this context, hydrophobic IR780 GUMBOS preferentially aggregated towards the center of
nanoparticles, whereas the hydrophilic PEG chain suspended outside of nanoparticles as a
stabilizer in an aqueous system. Similar phenomenon was also reported in other literature.28
Therefore, using such property of PEG-IR780 GUMBOS, the hydrophobic anticancer drug PTX
could be loaded into the hydrophobic domain of PEG-IR780 nanoGUMBOS. The schematic
process of formation of these nanoparticles is shown in Figure 4.4.

Self-assembly

Paclitaxel
PEG-IR780 GUMBOS

PTX/PEG-IR780 nanoGUMBOS

Figure 4.4. Schematic for formation of paclitaxel loaded nanoGUMBOS using PEGylated IR780
GUMBOS.
To synthesize these nanoGUMBOS with and without PTX loaded, a thin-film hydration
method was employed as described in the experimental section. Their morphology and size were
examined by use of transmission electron spectroscopy (TEM). Figure 4.5 depict TEM
micrographs of all PEG-IR780 nanoGUMBOS with and without PTX loaded. Examination of
these TEM micrographs indicates formation of quasi-spherical nanoparticles. TEM sizes are
summarized in Table 4.3, indicating a size range of nanoGUMBOS from 50 nm to 200 nm at dried
state. Interestingly, variation in their TEM size was observed for all the nanoparticles as PTX was
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loaded. For instance, size of PEG-[IR780][I] was approximately 48 ± 8 nm, while PTX loaded
PEG-[IR780][I] nanoparticles exhibited an increased size of 110 ± 15 nm. In contrast, all the PEGIR780 nanoGUMBOS including PEG-[IR780][NTF2], PEG-[IR780][BETI], and PEG[IR780][AOT] displayed a decrease in their TEM sizes upon PTX loading (Table 4.3). The
reduction in size could be most likely due to their counter-anions that play a role in the hydrophobic
interactions with PTX, leading to formation of more condensed hydrophobic core of these
nanoGUMBOS. Similar result has also been obtained for SN38-loaded nanoparticles.29
Table 4.3. A summary of TEM sizes of PEGylated nanoGUMBOS with and without PTX loaded.
Compound
PEG-[IR780][I]
PEG-[IR780][NTF2]

PEG-[IR780][BETI]

PEG-[IR780][AOT]

Drug/PEG
(mg/mg)

TEM Size (d.nm)

0/10

48 ± 8

1/10

110 ± 15

0/10
1/10

99 ± 12
74 ± 18

0/10

160 ± 26

1/10

87 ± 13

0/10

186 ± 23

1/10

128 ± 16

130

Figure 4.5. TEM micrographs of PEGylated nanoGUMBOS with and without PTX loaded.
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In addition to microscopic study of these nanoparticles in dried state, DLS and zeta
potential characterizations were performed to further examine their size distribution and surface
charge in solution. However, poor particle size distributions with large polydispersity index (PDI)
were observed for those nanoparticles without PTX loaded. Surprisingly, as PTX is loaded, all
nanoparticles exhibited a relatively narrow size distribution with a PDI less than 0.3. This result
suggests that incorporation of hydrophobic PTX drug aided in formation of more uniform
nanoparticles. In addition, these PTX loaded PEG-IR780 nanoparticles displayed slightly larger
particles sizes in solution than their sizes in dried state obtained by TEM measurements (Table 4.3
and 4.5). This could be attributed to the fact that solvated nanoparticles in aqueous solution was
measured by DLS. It is still noteworthy that their hydrodynamic size is within a range of less than
200 nm, which allows for effective passive tumor targeting using enhanced permeation and
retention (EPR) effects.30 Therefore, these PTX/PEG-IR780 nanoGUMBOS showed great
potential for future study of tumor targeted drug delivery. Zeta potential measurements were also
performed in 1X PBS at 7.4. As shown in Table 4.4, the zeta potential of PTX/PEG-[IR780][I],
PTX/PEG-[IR780][NTF2], PTX/PEG-[IR780][BETI], and PTX/PEG-[IR780][AOT] was +2.4
mV, +4.4 mV, +3.5 mV, and -13.8 mV, respectively. Such difference in their zeta potential was
most likely dependent upon their counter-anions. Furthermore, stability of these nanoparticles was
examined by monitoring hydrodynamic size in PBS over time. No significant variation in the size
of nanoGUMBOS was observed for up to 48h of storage at 4 oC (Figure 4.6), indicating excellent
stability of PEG-IR780 nanoGUMBOS in physiological environment. Analyses of these results
demonstrate that PTX can readily interact with PEG-GUMBOS, and aid in self-assembly into
stable nanoparticles.
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Figure 4.6. Hydrodynamic sizes of PTX loaded nanoGUMBOS with different anions at 0 h, 24 h,
48 h of storage at 4 °C in 1XPBS buffer solution (pH 7.4).
Subsequently, the PTX encapsulation efficiency (EE) and drug content (DC) of each PEGIR780 nanoGUMBOS were determined. As shown in Table 4.4, all nanoGUMBOS displayed a
good EE for loading PTX. It was interesting to note that the maximum EE of PTX was 90.6 %
with DC of 8.3% when using PEG-[IR780][AOT] as drug carrier, followed by PEG[IR780][BETI], PEG-[IR780][I], and PEG-[IR780][NTF2]. Further analysis of these results
suggests that higher EEs and DCs were achieved for nanoGUMBOS that consists of more
hydrophobic GUMBOS such as [IR780][AOT] and [IR780][BETI] relative to those consisting of
less hydrophobic GUMBOS such as [IR780][I] and [IR780][NTF2]. This study demonstrate that
hydrophobicity of GUMBOS plays an important role in interactions with PTX during drug
encapsulation process, further indicating strong potential of using GUMBOS strategy to enhance
the loading of hydrophobic drugs. Similar hydrophobic interactions were also observed for
preparation of protein based nanoparticles with lipophilic drug incorporated.31
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Table 4.4. Characteristics of PTX/PEG-IR780 nanoGUMBOS.
size (nm)a

Compound

PDIb

ZP (mV)c

EE (%)d

DC (%)e

PTX/PEG-[IR780][I]

152 ± 11

0.22 ±0.02

2.4 ± 0.6

44.1 ± 0.8

4.2 ± 0.1

PTX/PEG-[IR780][NTF2]

116 ± 8

0.23 ± 0.04

4.4 ± 0.3

41.3 ± 2.4

4.0 ± 0.2

PTX/PEG-[IR780][BETI]

134 ± 5

0.23 ± 0.01

3.5 ± 0.8

71.8 ± 5.3

6.7 ± 0.5

PTX/PEG-[IR780][AOT]

179 ± 5

0.26 ± 0.02

-13.8 ± 1.3

90.6 ± 4.4

a

b

c

8.3 ± 0.4
d

Hydrodynamic size (nm), Polydispersity Index (PDI), Zeta Potential (ZP) were determined using DLS. Encapsulation
Efficiency (EE) = amount of PTX loaded in nanoGUMBOS/ total amount of PTX used. eDrug Content (DC) = amount
of PTX loaded in nanoGUMBOS/ amount of PTX/IR780 nanoGUMBOS.

Following confirmation of the PTX loading capacity of these PEG-IR780 nanoGUMBOS,
drug release behavior was also investigated using a dialysis method. All nanoparticles were
dialyzed against 1XPBS (pH 7.4) at 37 oC, similar to the biological environment. As indicated in
Figure 4.7, PTX/PEG-[IR780][I] nanoparticles displayed a much faster release profile as compared
with other PEG-IR780 nanoGUMBOS. For instance, approximately 75% of PTX has been
released from PTX/PEG-[IR780][I] nanoparticles in the first 9 h, while less than 50% of PTX has
been released from other nanoGUMBOS including PTX/PEG-[IR780][NTF2], PTX/PEG[IR780][BETI], and PTX/PEG-[IR780][AOT] within the same period of time. In the following
hours, the release rate of PTX/PEG-[IR780][I] nanoparticles was reduced in comparison to the
previous release profile, but such sustained release has only been maintained up to 24 h until 100%
of PTX was all released. In terms of PTX/PEG-[IR780][NTF2] and PTX/PEG-[IR780][BETI],
they displayed a similar release profile and have shown a 100% of PTX release after 48 h. More
interestingly, PTX/PEG-[IR780][AOT] consisting of most hydrophobic GUMBOS released PTX
in a much slower manner than other nanocarriers. During the entire release process, PTX/PEG[IR780][AOT] displayed a sustained release of PTX without any obvious burst change for at least
72 h. These results could be most likely associated with the tendency that more hydrophobic
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GUMBOS on the end of PEGylated polymer would enhance their hydrophobic interactions with
PTX, which thus stabilize nanoGUMBOS and prevent drug leakage.
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Figure 4.7. Drug release profiles of all PEGylated nanocarriers.
4.3.3. Near Infrared Imaging Property
The integration of NIRF bio-imaging modality into drug delivery has attracted tremendous
attentions for imaging-guided cancer therapy, which allows to immediately track the delivery of
therapeutic drugs into tumor site.14, 32 In this study, PEG-IR780 nanoGUMBOS were not only
acting as a drug carrier of PTX but also a possible NIRF imaging agent for monitoring drug
delivery. Herein, their optical properties including absorption and fluorescence spectral were
investigated. As shown in Figure 4.8, all nanoparticles in water displayed a peak absorption at 782
nm with a shoulder 710 nm. Meanwhile, strong fluorescence intensities were observed with
emission maximum at 805 nm. These results demonstrated favorable optical properties of these
nanoGUMBOS for NIRF imaging due to incorporation of IR780 in the design.
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Figure 4.8. (a) Absorption spectra and (b) emission spectra of all PEGylated nanoGUMBOS in
water.
4.3.4. Protein Adsorption Study
PEGylation has been demonstrated to be an effective approach to improve bioavailability
of lipophilic drugs. Additionally, it can protect nanoparticles from non-specific protein adsorptions,
thus leading to enhanced circulation time in the body. 23 Given that serum albumins are the most
common studied binding proteins because of their size and binding sites;33 therefore, bovine serum
albumin (BSA) was selected as a model protein to investigate non-specific binding interactions
with nanoGUMBOS in conjunction with absorption spectroscopy. As shown in Figure 4.9, the
unmodified [IR780][I] displayed a broad absorption spectrum with a peak wavelength at 774 nm,
while the addition of BSA resulted in a narrow spectrum with a 14 nm red-shifted peak wavelength
at 788 nm. Furthermore, a dramatic increase in peak absorbance was observed as concentration of
BSA increased, indicating a strong interaction between IR780 and BSA. In contrast, almost
identical spectra of PEG-[IR780][I] were observed in spite of the increasing addition of BSA,
suggesting weak interactions between PEG-IR780 and BSA. Evaluation of these results confirmed
that PEGylation of IR780 can significantly improves stability of nanoparticles with minimum
interactions with proteins as compared to non-PEGylated IR780. This indicates that PEG-IR780
nanoGUMBOS can be used as a promising drug carrier.
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Figure 4.9. Absorption spectra of (a) [IR780][I] and (b) PEG-[IR780][I] after incubation with
different concentration of BSA.
4.3.5. In vitro Cytotoxicity of PTX/PEG-IR780 NanoGUMBOS
To evaluate the targeting property and anticancer effects of PTX/PEG-IR780
nanoGUMBOS, in vitro cytotoxicity experiments were performed using a colorimetric cell
viability MTT assay. One breast epithelial normal cell line, i.e. HMEC and two triple-negative
breast cancer cell lines including MDA-MB-231 and Hs578T were used as the model cell lines.
Firstly, cytotoxicity of drug-free nanoGUMBOS was evaluated using these three breast cell lines.
As shown in Figure 4.10, a dose-dependent cytotoxicity towards both cancer cell lines was
observed with treatment of all the drug-free PEG-IR780 nanoGUMBOS, which might result from
the chemotherapeutic effects of IR780-based nanoGUMBOS as demonstrated in my previous
study.22 In contrast, as concentration of nanoGUMBOS increased, cell viability of normal cells did
not vary significantly and maintained above 80%. These results demonstrated a selective toxicity
of PEG-IR780 nanoGUMBOS towards cancer cells, suggesting the cancer targeting and
chemotherapeutic properties of PEG-IR780 nanoGUMBOS. More interestingly, the selective
cytotoxicity of PEG-[IR780][BETI] and PEG-[IR780][AOT] towards both cancer cell lines were
statistically higher than PEG-[IR780][I] and PEG-[IR780][NTF2] as indicated by their smaller
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half-maximum inhibitory concentrations, i.e. IC50 (Table 4.5). This result further demonstrate the
tunability of GUMBOS due to counter-ion variation.
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Figure 4.10. Cytotoxicity of PEG-IR780 nanoGUMBOS towards (a) HMEC breast normal cells,
(b) MDA-MB-231 breast cancer cells, and (c) Hs578T breast cancer cells.
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Table 4.5. IC50 of PEG-IR780 nanoGUMBOS for treatment of MDA-MB-231 and Hs578T
cancer cell lines.
MDA-MB-231

Hs578T

(µg/mL)

(µg/mL)

PEG-[IR780][I]

12.6 ± 0.4

13.4 ± 0.8

PEG-[IR780][NTF2]

12.8 ± 0.5
8.4 ± 0.3
8.0 ± 0.3

13.7 ± 0.8
11.8 ± 0.7
9.8 ± 0.6

Compound

PEG-[IR780][BETI]
PEG-[IR780][AOT]

Furthermore, therapeutic effects of PTX loaded nanoGUMBOS were also examined in
vitro using two breast cancer cell lines, which can provide a better insight into the capability of
these nanoGUMBOS for drug delivery. As shown in Table 4.6, all drug-loaded nanoGUMBOS
displayed very similar cytotoxicity, which could be a combined result of their release behaviors
and the intrinsic chemotherapeutic properties as discussed previously. For example, PEG[IR780][I] has shown less cytotoxicity (Table 4.5) but with a more rapid drug release profile than
PEG-[IR780][AOT] (Figure 4.6). Herein, the rapid drug release behavior of PEG-[IR780][I]
compensated for its relatively low cytotoxicity. As a result, very similar IC50 values of 0.32 ± 0.03
µg/mL and 0.24 ± 0.08 µg/mL were obtained for PTX/PEG-[IR780][I] and PTX/PEG[IR780][AOT], respectively. Most importantly, a significant reduction in IC50 was observed for all
PTX loaded nanoGUMBOS when comparing with free PTX. In Table 4.6, MDA-MB-231
cytotoxicity revealed an IC50 of PTX/PEG-[IR780][AOT] to be 0.24 µg/mL, which is more than
10-fold decrease

as compared to that of free PTX with IC50 value of 3.37 µg/mL. This

nanoGUMBOS also outperformed free PTX in terms of cytotoxicity towards Hs578T cancer cells,
showing approximately 4-fold decreased IC50 concentration. Such enhanced cytotoxicity could be
attributed to the synergetic chemotherapeutic effects from both nanoGUMBOS and PTX, which
thus also suggests potential application of these PTX/PEG-IR780 nanoGUMBOS for combination
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therapy. From these studies, I demonstrated the multifunctional properties of PEG-IR780
nanoGUMBOS as promising chemotherapeutics and drug carriers.
Table 4.6. IC50 of PTX/PEG-IR780 nanoGUMBOS for treatment of MDA-MB-231 and Hs578T
cancer cell lines.

Compound

IC50 in µg/mL of PTX for 24 h incubation
MDA-MB-231

Hs578T

PTX

3.37 ± 0.09

0.35 ± 0.01

PTX/PEG-[IR780][I]

0.32 ± 0.03

0.093 ± 0.02

PTX/PEG-[IR780][NTF2]

0.33 ± 0.01
0.29 ± 0.09
0.24 ± 0.08

0.081 ± 0.02
0.068 ± 0.04
0.078 ± 0.03

PTX/PEG-[IR780][BETI]
PTX/PEG-[IR780][AOT]

4.3.6. Subcellular Localization of PTX/PEG-IR780 NanoGUMBOS
IR780 has shown a selective accumulation in the mitochondria.34 In my previous study, it
has been demonstrated that counter-ion variation has negligible effects on the mitochondrial
localization of IR780 based nanoGUMBOS. Here, I further examined the impact of PEGylation
on the subcellular localization of IR780. MDA-MB-231 cells were incubated with one of the
PEGylated nanoGUMBOS, PEG-[IR780][AOT] and co-stained with MitoTracker green dye and
LysoTracker red dye prior to observation using fluorescence microscopy. As shown in Figure 4.11,
strong intracellular red fluorescence from PEG-nanoGUMBOS were observed, indicating their
efficient internalization into cancer cells. Meanwhile, this result further confirmed that such
nanoGUMBOS have great potential for cell imaging, thus allowing for monitoring cellular uptake,
intracellular release as well as delivery of anticancer drug. In addition, subcellular localization
studies demonstrated significant co-localization of nanoGUMBOS with MitoTracker but minimal
co-localization with LysoTracker, indicating that PEGylated nanoGUMBOS were primarily
localized in the mitochondria in breast cancer cells.
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Figure 4.11. Co-localization images of MDA-MB-231 cancer cells treated with PEG[IR780][AOT] nanoGUMBOS for 0.5 h. The images show nanoGUMBOS fluorescence in cells
(red), MitoTracker fluorescence in mitochondria (green), and LysoTracker fluorescence (cyan) in
lysosomes. These images were captured by use of fluorescence microscope.
4.4. Conclusions
In this study, I designed and synthesized a series of multifunctional PEGylated IR780based GUMBOS with varying anions. These GUMBOS having an amphiphilic structure were
subsequently converted to nanoGUMBOS to load anticancer drug, PTX, via self-assembly
mechanism. All drug-loaded nanoGUMBOS have displayed a spherical shape with a size range
from 74 nm to 128 nm as characterized by TEM measurements. It was also interesting to observe
that GUMBOS with bulky counter-anion resulted in formation of more condensed nanoparticles
after drug loading, showing a decrease in TEM size. In addition, variation in the counter-anion of
GUMBOS resulted in a tunable hydrophobicity, which was shown to have an impact on drug
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loading and drug release profiles of each nanocarrier. With increasing hydrophobicity of
GUMBOS, the resulting nanoGUMBOS showed an enhanced drug loading and more sustained
drug release under physiological condition. Furthermore, these nanocarriers themselves displayed
intense emission in the NIR region, selective toxicity towards cancer cells, and mitochondria
targeting property, indicating strong potential for NIRF imaging and chemotherapeutic
applications. Moreover, significantly enhanced in vitro cancer killing activity of the PTX-loaded
nanoGUMBOS was observed in comparison to free PTX, indicating highly effective delivery of
PTX to cancer cells. In conclusion, this work provides a new and simple strategy to design and
fabricate multifunctional nanocarriers that can be used for applications in simultaneous imaging,
combination therapy, and drug delivery.
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CHAPTER 5. CONCLUSIONS AND FUTURE WORK
5.1. Conclusions
In this dissertation, the primary focus was on development of near infrared (NIR) IR780based GUMBOS and nanoGUMBOS for applications in chemotherapy, photothermal therapy, and
drug delivery. Using several strategies, a series of IR780-based nanoGUMBOS were prepared with
desired properties that are promising for cancer treatment. In Chapter 2, synthesis, characterization
and chemotherapeutic applications of IR780-based nanoGUMBOS were reported. These
nanoGUMBOS were prepared by direct conversion of hydrophobic GUMBOS into nanoparticles
using a reprecipitation method. All nanoGUMBOS display tunable cytotoxicity toward cancer
cells while maintaining minimum toxicity toward normal cells with anion variations. Most
importantly, significantly improved chemotherapeutics effects in vitro were observed for all
nanoGUMBOS as compared to the parent dye. In Chapter 3, CD-based IR780 nanoGUMBOS
were developed and evaluated for chemo/photothermal therapeutic effects both in vitro and in vivo.
Preparation of such nanoGUMBOS integrated a cyclodextrin complexing strategy. As a result,
these CD-based nanoGUMBOS display enhanced aqueous stability, photo-stability, photothermal
effects, and selective cytotoxicity towards cancer cells in comparison with the parent dye, IR780
and control nanoGUMBOS without CD. Additionally, such nanoGUMBOS retain the inherent
tumor targeting property of IR780 while also displaying prolonged tumor retention, thus resulting
in enhanced chemo/photothermal therapeutic effects of CD-based nanoGUMBOS upon NIR laser
irradiation. Chapter 4 discusses development of multifunctional nanocarriers using PEG-IR780

GUMBOS for drug delivery. Benefiting from PEGylation and IR780-based GUMBOS, the
resulting PEG-IR780 nanoGUMBOS exhibit excellent aqueous stability, strong near infrared
fluorescence, as well as tunability in drug loading and drug release profiles upon varying the anion
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of GUMBOS. Most importantly, such nanoGUMBOS can effectively deliver the anticancer drug
paclitaxel to cancer cells. As indicated by in vitro cytotoxicity studies, enhanced cancer killing
activities of paclitaxel loaded PEG-IR780 nanoGUMBOS were observed as compared to free
paclitaxel. Results in this study demonstrate a simple combination strategy for design of
multifunctional nanocarriers. Thus, through these studies in this dissertation, it can be concluded
that the flexibility of GUMBOS and nanoGUMBOS provide many advantages to be used for
development of a variety of novel therapeutics for biomedical applications.
5.2. Future Work
In this dissertation, all synthesized GUMBOS and nanoGUMBOS were derived from an
active IR780 cation in combination with a variety of inert anions for biomedical applications. The
observed tunable anticancer effects and drug loading efficiency of nanoGUMBOS are primarily
attributed to anion variations. To confirm the tunability of GUMBOS in pharmaceutics, more
GUMBOS from anionic compounds need to be investigated upon variation in the cation. Moreover,
it would also be interesting to develop GUMBOS using two pharmaceutically active ions, which
could possibly result in synergetic effects and thus enhanced drug efficacy.
In addition, while PEGylated nanoGUMBOS proved to be promising nanocarriers for
paclitaxel in vitro, there are still many multifunctional properties requiring further investigation
prior to clinical application. Firstly, given that PEGylated nanoGUMBOS have excellent aqueous
stability and promising selective toxicity towards breast cancer cells in vitro, this material can be
further evaluated in vivo as a chemotherapeutic drug. Secondly, the incorporation of IR780 in this
material may also allow for PDT and PTT applications. Finally, pharmacokinetics, systemic
toxicity, and in vivo anticancer efficacy of paclitaxel loaded nanoGUMBOS can be extensively
evaluated in future studies.
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